Introduction {#s1}
============

Vpr is a highly conserved HIV accessory protein that is necessary for optimal replication in macrophages ([@bib5]) but its mechanism of action is poorly understood. Studies using human lymphoid tissue (HLT), which are rich in both T cells and macrophages, have found that loss of Vpr decreases virus production ([@bib62]) but only when the virus strain used is capable of efficiently infecting macrophages ([@bib20]). These studies provide evidence that Vpr enhances infection of macrophages and increases viral burden in tissues where macrophages reside. Because Vpr is packaged into the virion ([@bib14]) and localizes to the nucleus ([@bib46]), it may enhance early viral replication events. However, in mononuclear phagocytes *vpr*-null virus in which Vpr protein is provided by trans-complementation in the producer cells replicates poorly compared to wild-type virus ([@bib17]), indicating that Vpr's role in the HIV replication cycle continues into late stages.

Previous work by our group demonstrated that Vpr counteracts an unidentified macrophage-specific restriction factor that targets Env and Env-containing virions for lysosomal degradation ([@bib48]; [@bib15]). This restriction could be conferred to permissive 293T cells by fusing them with MDM to create 293T-MDM heterokaryons. A follow up study demonstrated that by increasing steady state levels of Env, Vpr increases formation of virological synapses between infected MDM and autologous uninfected T cells, enhancing HIV infection of T cells ([@bib15]). This enhances spread to T cells and dramatically increases levels of Gag p24 in the culture supernatant. This finding helps explain the paradoxical observations that Vpr is required for maximal infection of T cells in vivo ([@bib28]) but numerous studies have shown Vpr only marginally impacts infection of pure T cell cultures in vitro (e.g. [@bib48]).

Our goal in the current study was to identify and characterize the myeloid restriction factor targeting Env that is counteracted by Vpr. We reasoned that macrophage-specific Env-binding proteins, including the carbohydrate binding protein mannose receptor (MR), were candidates. MR is expressed on several types of macrophages in vivo ([@bib43]; [@bib44]) and is known to mediate innate immunity against various pathogens ([@bib47]; [@bib72]). MR recognizes mannose-rich structures including high-mannose glycans, which are incorporated in many proteins during synthesis. In eukaryotic cells most high-mannose glycans are cleaved by α-mannosidases and replaced with complex-type glycans as they transit through the secretory pathway. By contrast, in prokaryotic cells, high-mannose residues remain intact, making them a useful target of pattern recognition receptors including MR. Some viral proteins, including HIV-1 Env, evade mannose trimming ([@bib18]) and retain enough high-mannose to bind MR ([@bib76]; [@bib36]). There is evidence that HIV-1 proteins Nef and Tat decrease expression of MR based on studies performed in monocyte derived macrophages (MDM) and the monocytic U937 cell line, respectively ([@bib10]; [@bib79]). Nef dysregulates MR trafficking using an SDXXLΦ motif in MR's cytoplasmic tail ([@bib79]), which is similar to the sequence in CD4's tail that Nef uses to remove it from the cell surface ([@bib8]; [@bib24]; [@bib13]). Whether MR or its modulation by viral proteins alters the course of viral replication has not been established.

Here we confirm that Nef reduces MR expression in primary human MDM, although in our system, the effect of Nef alone was relatively small. In contrast, we report that co-expression of Vpr and Nef dramatically reduced MR expression. In the absence of both Vpr and Nef, MR levels normalized indicating that Tat did not play a significant, independent role in MR downmodulation. Deleting mannose residues on Env or silencing MR alleviated mannose-dependent interactions between MR and Env and reduced the requirement for Vpr. Although the post-infection interactions between MR and Env reduced Env levels and inhibited viral release, we provide evidence that these same interactions were beneficial for initial infection of MDM. Together these results reveal that mannose residues on Env and the accessory proteins Nef and Vpr are needed for HIV to utilize and then disable an important component of the myeloid innate response against pathogens intended to thwart infection.

Results {#s2}
=======

Identification of a restriction factor counteracted by Vpr in primary human monocyte-derived macrophages {#s2-1}
--------------------------------------------------------------------------------------------------------

Because we had previously determined that Vpr functions in macrophages to counteract a macrophage specific restriction factor that targets Env, we reasoned that Env-binding proteins selectively expressed by macrophages were potential candidate restriction factors. To determine whether any factors fitting this description were targeted by Vpr, we cultured macrophages under conditions that achieve a saturating infection by both wild-type and Vpr-null mutant viruses ([Figure 1A and B](#fig1){ref-type="fig"}). We found that mannose receptor (MR), which is highly expressed on macrophages and has been previously shown to bind Env ([@bib76]; [@bib22]; [@bib36]), was significantly decreased by wild-type HIV 89.6 but not by 89.6 *vpr*-null ([Figure 1C and D](#fig1){ref-type="fig"}, p\<0.01). In contrast, we observed no significant effect of Vpr on the expression of GAPDH. We also observed that stimulator of interferon genes (STING) was unaffected by Vpr ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Relative expression of known restriction factors GBP5 and IFITM3 varied in infected MDM from multiple donors ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), but unlike MR they were not consistently reduced in the wild-type condition, indicating they are not targeted by Vpr.

![HIV Vpr reduces steady state levels of host mannose receptor in MDM and increases steady state levels of viral Env protein.\
(**A**) Diagram of the HIV 89.6 proviral genome. The shaded box shows the location of *vpr,* which was disrupted by a frame shift mutation to create the Vpr-null version ([@bib48]). HIV-1 89.6 is a dual CXCR4/CCR5-tropic HIV molecular clone isolated from the peripheral blood of an AIDS patient ([@bib16]). (**B**) Summary graph depicting MDM infected by HIV 89.6 wild-type and *vpr*-null with matched infection frequencies of at least 50% 10 days post infection as measured flow cytometrically by intracellular Gag p24 staining. This subset with high frequencies of infection was selected to examine potential effects on host factors. (**C**) Western blot analysis of whole cell lysates from MDM prepared as in B. (**D**) Summary graph displaying relative expression of MR in wild-type and mutant 89.6 from blots as shown in C. Western blot protein bands were quantified using a Typhoon scanner. Values for MR expression in MDM infected with Vpr-null HIV were normalized to GAPDH and then to wild-type for each donor. Statistical significance was determined using a two-tailed, ratio *t*-test. \*\*p=0.005 (**E**) Western blot analysis of HIV protein expression in MDM infected as in B. (**F**) Summary graph of HIV protein expression from western blot analysis as in E and quantified as described in methods. The ratio of expression in wild-type to *vpr*-null infection is shown. Data from 9 independent donors with similar frequencies of infection (within 2-fold) following ten days of infection are shown. Statistical significance was determined using a two-tailed, ratio *t*-test, N.S. -- not significant, p=0.31, \*\*p\<0.01, \*\*\*p\<0.001. Data from each donor is represented by the same symbol in all charts. Mean values are indicated.](elife-51035-fig1){#fig1}

To confirm the effect of Vpr on Env during HIV infection of primary human macrophages in which MR was downmodulated, we performed quantitative western blot analysis. As shown in [Figure 1E and F](#fig1){ref-type="fig"}, we confirmed that amounts of Vpr sufficient for MR downmodulation were also sufficient for stabilizing expression of Env (gp160, gp120, gp41). Compiled data from nine donors clearly demonstrated results that were similar to our prior publication ([@bib48]); under conditions of matched infection in which there was no significant difference in HIV Gag pr55 levels between wild-type and *vpr*-null infections, all three forms of Env were significantly more abundant in the wild-type infection (gp160: 4-fold, p\<0.002; gp120: 6-fold, p\<0.002; gp41: 3-fold, p\<0.001).

Vpr and Nef counteract MR expression in infected macrophages via independent and additive mechanisms {#s2-2}
----------------------------------------------------------------------------------------------------

Because an earlier report indicated that Nef decreases surface expression of MR ([@bib79]), we asked whether Nef was playing a role in MR downmodulation in our systems. Because HIVs lacking Vpr and Nef spread too inefficiently in MDM to observe effects on host proteins by western blot analysis, we utilized a replication defective HIV with a GFP marker (NL4-3 ∆GPE-GFP, [Figure 2A](#fig2){ref-type="fig"}) to allow measurement of MR expression via flow cytometry following single-round transduction. This construct has the additional advantage that it eliminates potentially confounding effects of differences between wild-type and mutant HIV viral spread. We generated truncation mutations in *nef* and *vpr* and confirmed that these mutations only affected expression of the altered gene product in transfected 293T ([Figure 2B](#fig2){ref-type="fig"}). For these experiments, primary MDM were harvested earlier than the experiments described in [Figure 1](#fig1){ref-type="fig"} (five days versus ten days) because the viruses could not replicate and the GFP marker allowed identification of transduced cells ([Figure 2C](#fig2){ref-type="fig"}). Under these conditions, we found that MR expression was dramatically reduced in a subset of GFP^+^ cells when both Vpr and Nef were expressed ([Figure 2C--E](#fig2){ref-type="fig"}). Both Nef and Vpr contributed to MR downmodulation; loss of function mutation in either Vpr or Nef reduced the severity of MR downmodulation similarly, and there was no statistical difference between MR levels in macrophages expressing either Vpr or Nef alone ([Figure 2E](#fig2){ref-type="fig"}). In addition, complete elimination of downmodulation required mutation of both Vpr and Nef ([Figure 2C--E](#fig2){ref-type="fig"}). These results indicate that both Vpr and Nef are required for maximal MR downmodulation in HIV-infected macrophages and that neither alone is sufficient.

![Combined effects of Nef and Vpr completely remove MR from a significant proportion of infected cells at early time points.\
(**A**) Diagram of HIV NL4-3 ∆GPE-GFP. (**B**) Western blot analysis of whole cell lysates from 293T cells transfected with the indicated viral expression construct. (**C**) Flow cytometry plots indicating the gating strategy used to identify live GFP^+^ vs GFP^-^ cells and the fraction of cells that are MR^low^. (**D**) Representative flow cytometric analysis of MDM at five days post transduction by the indicated virus. The percentage of GFP^+^ cells that fell into the MR^low^ gate is indicated in each panel. (**E**) Summary graph depicting the percentage of GFP^+^ cells that fell into the MR^low^ gate in transduced MDM. For the uninfected column the results from GFP^-^ cells are displayed. (Each dot indicates an independent donor, range 3--11). (**F**) Western blot analysis of whole cell lysates from 293T cells transfected with the indicated viral expression construct. (**G**) Summary graph depicting the frequency of transduced (GFP^+^) MDM at the time of harvest. (**H**) Representative flow cytometric plots of MDM transduced with the indicated adenoviral vector (*n* = 3 independent donors). For parts E and F mean +/- standard deviation is shown. Statistical significance was determined by a two-tailed, paired *t*-test. N.S. not significant, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001.](elife-51035-fig2){#fig2}

Vpr was previously demonstrated to interact with a cellular co-factor called DCAF1, a component of the cellular DCAF1-DDB1-CUL4 E3 ubiquitin ligase complex. ([@bib30]; [@bib38]; [@bib50]; [@bib35]; [@bib81]; [@bib83]). The interaction between Vpr and DCAF1 can be disrupted through a Vpr mutation (Q65R) that inhibits many Vpr-dependent functions, including reversal of Env degradation in macrophages ([@bib48]). To determine whether this mutant is defective at MR downmodulation, we generated the mutation in the NL4-3 ∆GPE-GFP parent ([Figure 2A](#fig2){ref-type="fig"}), confirmed expression in transfected 293T cells ([Figure 2F](#fig2){ref-type="fig"}) and tested the effect of the mutation on MR levels in macrophages. As expected, we found that in transduced MDM the *vpr*-Q65R mutant behaves similarly to *vpr*-null ([Figure 2E](#fig2){ref-type="fig"}). These results indicate interactions between Vpr and DCAF1 are required to mediate Vpr's effects on MR.

The differences in MR downmodulation we observed using this system were not due to variations in multiplicity of infection of the different viral constructs as MDM transduced with the mutant viral constructs had roughly similar transduction rates as the parental construct ([Figure 2G](#fig2){ref-type="fig"}) but demonstrated less MR downmodulation ([Figure 2E](#fig2){ref-type="fig"}).

To determine whether the relatively modest effect of Nef alone on MR levels was due to using HIV to deliver Nef as compared to an adenoviral vector delivery system used in a prior publication ([@bib79]), we repeated the experiment using an adenoviral vector expressing Nef. These experiments confirmed that levels of Nef sufficient to downmodulate the HIV receptor, CD4, on nearly all MDM in the culture achieved only modest effects on MR in a subset of cells ([Figure 2H](#fig2){ref-type="fig"}) similar to what was observed using the HIV reporter construct ([Figure 2E](#fig2){ref-type="fig"}). Thus, Nef and Vpr have modest but significant effects on MR when expressed individually, however the combined effects of both proteins can achieve nearly complete downmodulation at least in a subset of infected cells.

While the effect of Nef has been previously reported and found to be due to disruption of MR intracellular trafficking ([@bib79]), the effect of Vpr on MR is a novel observation. Vpr is known to target cellular proteins involved in DNA repair pathways for proteasomal degradation via interactions with Vpr binding protein \[DCAF1, ([@bib50])\]. Using this mechanism, Vpr degrades the uracil deglycosylases UNG2 and SMUG1 in 293T cells following co-transfection ([@bib65]; [@bib66]). To determine whether Vpr directly targets MR using a similar strategy, we co-transfected NL4-3 ∆GPE-GFP or a *vpr*-null derivative with expression vectors encoding an UNG2-FLAG fusion protein or MR ([@bib45]) in 293T cells. We then analyzed expression of MR or UNG2 by flow cytometry and western blot ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). We found that Vpr in 293T cells virtually eliminated UNG2 expression when measured by flow cytometry and noticeably reduced UNG2 by western blot. However, Vpr had no effect on expression of MR measured by either method. Thus, we concluded that Vpr does not degrade MR by the direct, proteasomal mechanism it uses to degrade UNG2. Because MR expression in this system is controlled by a heterologous CMV promoter; the lack of effect by Vpr suggested its action may depend on MR's native promoter.

Vpr reduces transcription of MRC1 {#s2-3}
---------------------------------

In addition to targeting proteins for degradation, Vpr also functions to inhibit transcription of genes such as *IFNA1* ([@bib34]; [@bib48]). Therefore, we hypothesized that Vpr may reduce MR expression via inhibition of transcription. To examine this, we assessed transcriptional activity in primary human MDM transduced with the wild-type or Vpr-null reporter virus ([Figure 3A](#fig3){ref-type="fig"}) using cells isolated based on GFP expression ([Figure 3B](#fig3){ref-type="fig"}). We found that the MR gene (*MRC1*) was consistently reduced in cells transduced by *vpr*-competent virus compared to cells transduced by *vpr*-null virus ([Figure 3C and D](#fig3){ref-type="fig"}, p=0.001). In contrast, any effects of Vpr on the housekeeping genes *ACTB* (β-actin) and *POL2A* (RNA polymerase 2A) were significantly smaller ([Figure 3D](#fig3){ref-type="fig"}, p\<0.01). Similar results were obtained when each gene was normalized to *ACTB* instead of *GAPDH* ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}). The magnitude of the effect on *MRC1* is consistent with prior reports of HIV-1 inhibiting *MRC1* transcription− though this was not previously linked to Vpr ([@bib33]; [@bib73]). Relative *MRC1* expression in untransduced MDM was heterogeneous, varying over a ten-fold range. When compiled across donors, *MRC1* levels in mock-transduced samples were not significantly different than transduced ([Figure 3---figure supplement 1C--F](#fig3s1){ref-type="fig"}).

![Vpr reduces transcription of *MRC1*.\
(**A**) Diagram of HIV NL4-3 ∆GPE-GFP. (**B**) Flow cytometry plots indicating the gating strategy used to sort live GFP^+^ vs GFP^-^ cells for subsequent qPCR analysis. (**C**) Summary graph of mannose receptor (*MRC1*), β-actin (*ACTB*) and RNA Polymerase 2A (*POL2A*) mRNA expression in MDM transduced with the indicated HIV reporter and sorted for GFP expression by FACS. All data are normalized to *GAPDH* mRNA expression. (**D**) Summary graph of *MRC1*, *ACTB* and *POL2A* expression normalized to the Vpr-null condition in each donor. (*n* = 7 independent donors). Geometric mean +/- geometric standard deviation is shown. Statistical significance was determined by a two-tailed, ratio *t*-test. N.S. = not significant p=0.81, \*\*p\<0.01.](elife-51035-fig3){#fig3}

Combined effect of Vpr and Nef dramatically enhances Env levels in primary human MDM {#s2-4}
------------------------------------------------------------------------------------

To determine whether the striking downmodulation of MR we observed with expression of both Nef and Vpr affected viral spread in MR^+^ macrophages, we generated additional mutations in HIV-1 89.6 to create a *nef*-null mutant and a *vpr-nef*-null double mutant. As expected, in transfected 293T cells these mutations did not alter Env protein levels ([Figure 4A](#fig4){ref-type="fig"}) or release of virions as assessed by measuring Gag p24 in the supernatant by ELISA ([Figure 4B](#fig4){ref-type="fig"}). However, in primary human MDM infected with these HIVs, the mutants demonstrated defects in viral spread, with the double mutant having the greatest defect ([Figure 4C and D](#fig4){ref-type="fig"}). The defect in spread was caused in part by diminished virion release, which we previously showed occurred in the absence of Vpr ([@bib48]); MDM infected with the HIV mutants released less Gag p24 even after adjusting for the frequency of infected cells ([Figure 4D](#fig4){ref-type="fig"}, right panel).

![Combined effect of Vpr and Nef dramatically enhances Env levels in primary human MDM.\
(**A**) Western blot analysis of whole cell lysate from 293T transfected with the indicated HIV construct. (**B**) Summary graph of virion release from 293T cells transfected as in A and measured by Gag p24 ELISA. (*n* = 5 independent transfections). The mean +/- standard deviation is shown. Statistical significance was determined by one-way ANOVA. (N.S. -- not significant) (**C**) Frequency of infected primary human MDM infected with the indicated HIV and analyzed over time by flow cytometric analysis of intracellular Gag. (For parts C-E, *n* = 2 independent donors). (**D**) Virion release by primary human MDM infected with the indicated HIV and analyzed by Gag p24 ELISA 10 days post infection. In the right panel, virion release was adjusted for frequency of infected cells as measured in part C. (**E**) Western blot analysis of whole cell lysate from primary human MDM infected with the indicated HIV. Within each donor, lanes 2--6 are a serial dilution series of the wild-type sample. The arrows below the Gag pr55 bands indicate the dilution of wild-type that has approximately the same amount of Gag pr55 as the *vpr-nef*-null double mutant.](elife-51035-fig4){#fig4}

To determine whether combined effects of Nef and Vpr on MR expression affected Env restriction, we assessed Env levels in primary human MDM infected with each construct. Because the frequency of infected cells as assessed by intracellular Gag staining ([Figure 4C](#fig4){ref-type="fig"}) and Gag pr55 western blot ([Figure 4E](#fig4){ref-type="fig"}) was lower in the mutants than in the wild-type infection, lysate from the wild-type sample was serially diluted to facilitate comparisons. Remarkably, we found that the *vpr-nef*-null double mutant, which retains near normal MR levels, exhibited the greatest defect in Env expression ([Figure 4E](#fig4){ref-type="fig"}, compare lanes with similar Gag as indicated). In sum, Vpr and Nef-mediated downmodulation of MR correlated inversely with Env levels, consistent with MR being the previously described but unidentified HIV restriction factor that targets Env for lysosomal degradation in macrophages and is counteracted by Vpr ([@bib48]). Combined effects of Nef on MR and other Env binding proteins including CD4 ([@bib3]) and chemokine receptors ([@bib54]) may also play a role in stabilization of Env.

Mannose-containing glycans in Env are required for macrophage restriction of HIV in the absence of Vpr {#s2-5}
------------------------------------------------------------------------------------------------------

A particularly dense mannose-containing structure on Env, known as the mannose patch, may mediate interactions between Env and MR. This structure is present on all HIV Env proteins that require Vpr for stability in macrophages \[89.6, NL4-3 and AD8 ([@bib48]; [@bib15]). Interestingly, a macrophage tropic strain YU-2, which was isolated from the CNS of an AIDS patient ([@bib42]), lacks a mannose patch. This structure is the target of several broadly neutralizing antibodies including 2G12, to which YU-2 is highly resistant ([@bib75]). If Vpr targets MR to counteract detrimental interactions between MR and mannose residues on Env, we hypothesized that HIV Envs lacking a mannose patch would have a reduced requirement for Vpr. To test this hypothesis, we first examined the extent to which virion release and Env expression were influenced by Vpr in primary human MDM infected with YU-2 or 89.6 HIVs. Consistent with our hypothesis, we observed no significant difference in Gag p24 release between wild-type and *vpr*-null YU-2 infection of MDM ([Figure 5A](#fig5){ref-type="fig"}). Moreover, the *vpr*-null mutant of YU2 displayed only a minor defect in Env expression compared to Vpr null versions of 89.6 and NL4-3 ([Figure 5B](#fig5){ref-type="fig"}).

![HIV YU2, which lacks a mannose-rich patch, does not require Vpr for robust Env protein expression and spread in MDM.\
(**A**) Virion release over time by primary human MDM infected with the indicated HIV as measured by ELISA (*n* = 2 independent donors). (**B**) Western blot analysis of whole cell lysates from MDM infected for 10 days with the indicated HIV. Because NL4-3 infects MDM poorly, NL4-3 was pseudotyped with a YU-2 Env expression plasmid co-transfected in the producer cells as described in Methods. Subsequent spread was blocked in all samples by the addition of entry inhibitors AMD3100 and maraviroc initially added 48 hr post-infection and maintained throughout the culture period. (**C**) Diagram of the HIV NL4-3 genome. The shaded portion represents the sequence that was replaced with sequence from HIV YU2 to create the NL4-3 *env*^YU-2^ chimera. (**D**) Western blot analysis of 293T cells transfected with the indicated HIV constructs. YU-2 gp41 is detected by the monoclonal antibody z13e1 and NL4-3 gp41 is detected by the monoclonal antibody CHESSIE-8. (**E**) Virion release from 293T transfected as in D as measured by p24 ELISA. (*n* = 3 experimental replicates). (**F**) Relative infection of MOLT4-R5 cells 48 hr after inoculation with the indicated viruses and treatment with entry inhibitors as indicated. The frequency of infected cells was measured by intracellular Gag stain and normalized to the untreated condition for each infection. (**G**) Western blot analysis of primary human MDM infected for 10 days with the indicated virus as in B. (*n* = 2 independent donors). (**H**) Summary graph showing virion release as measured by p24 ELISA from primary human MDM infected as in G. Virus production was adjusted for infection frequency as determined flow cytometrically using an intracellular Gag stain. The mean +/- standard deviation is shown. (*n* = 4 independent donors). N.D. -- no difference. Statistical significance was determined using a two-tailed, ratio *t*-test. N.S. -- not significant, \*p\<0.05.](elife-51035-fig5){#fig5}

Because there are a number of other genetic differences between YU-2 and the other HIVs, we constructed a chimeric virus, which restricted the differences to the *env* open reading frame. As shown in [Figure 5C](#fig5){ref-type="fig"}, a fragment of the YU-2 genome containing most of *env* but none of *vpr* ([Figure 5C](#fig5){ref-type="fig"}, shaded portion) was cloned into NL4-3 and NL4-3 *vpr*-null. As expected, these genetic alterations did not affect Env protein levels or virion release in transfected 293T cells ([Figure 5D and E](#fig5){ref-type="fig"}). To confirm that the chimeric Env was still functional, we examined infectivity in T cells prior to performing our analyses in primary human MDM. Conveniently, sequence variation within the gp120 region allows YU-2 Env to only utilize the co-receptor CCR5 for entry, whereas NL4-3 can only utilize CXCR4. Thus, we expected the NL4 3*env*^YU2^ chimera would switch from being CXCR4- to CCR5-tropic. To test this, we utilized a T cell line expressing both chemokine receptors (MOLT4-R5) and selectively blocked entry via CXCR4 and CCR5 entry inhibitors \[AMD3100 and maraviroc, respectively ([Figure 5F](#fig5){ref-type="fig"})\]. As expected, entry into MOLT4-R5 cells by NL4-3 was blocked by AMD3100 but not maraviroc, indicating CXCR4-tropism. The chimeric NL4-3 *env*^YU2^ and wild-type YU-2 demonstrated the inverse pattern, indicating CCR5-tropism. These results demonstrated that we had made the expected changes in the chimeric Env without disrupting its capacity to infect cells.

To determine whether swapping a limited portion of YU-2 *env* into NL4-3 alleviated the requirement for Vpr, we examined Env expression and virion release in primary human MDM infected with these viruses. Because the parental NL4-3 virus required pseudotyping with a macrophage-tropic Env for entry and was unable to spread in MDM, all infections were treated with entry inhibitors AMD3100 and maraviroc starting at 48 hr after inoculation and maintained throughout the culture period to block subsequent rounds of infection. Consistent with our hypothesis that YU-2 Env lacked determinants necessary for the restriction that was alleviated by Vpr, we observed that wild-type NL4-3 Env but not chimeric NL4-3 *env*^YU2^ required Vpr for maximal expression ([Figure 5G](#fig5){ref-type="fig"}). Moreover, MDM infected with the chimeric HIV had a reduced requirement for Vpr for maximal virion release ([Figure 5H](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This experiment provides strong evidence that the requirement for Vpr can be alleviated by genetic changes within the *env* open reading frame. These results are consistent with a model in which YU-2 *env* confers resistance to the effects of MR due to the absence of the mannose-rich structure on the YU-2 Env glycoprotein.

Deletion of N-linked glycosylation sites in Env reduces Env restriction in HIV infected human primary MDM and diminishes the need for Vpr and Nef {#s2-6}
-------------------------------------------------------------------------------------------------------------------------------------------------

To more directly assess the role of mannose in restricting expression of Env in HIV-1 infected primary human MDM, we engineered a version of 89.6 Env in which two N-linked glycosylation sites, N230 and N339 (HIV HxB2 numbering) were deleted by substituting non-glycosylated amino acids found at analogous positions in YU-2 Env ([Figure 6A](#fig6){ref-type="fig"}). The glycosylation sites N230 and N339 were selected because they contain high-mannose glycan structures ([@bib40]) that are absent in YU-2 Env. Loss of N230 limits neutralization by glycan specific antibodies ([@bib31]). Loss of N339 decreases the amount of oligomannose (Man~9~GlcNAc~2~) present on gp120 by over 25%, presumably by opening up the mannose patch to processing by α-mannosidases ([@bib59]). These substitutions (N230D and N339E) in 89.6 did not alter virion production ([Figure 6B](#fig6){ref-type="fig"}) or Env protein expression ([Figure 6C](#fig6){ref-type="fig"}) in transfected 293T cells.

![Deletion of N-linked glycosylation sites in *env* reduces the requirement for Vpr and Nef for virion release and Env expression in HIV-1 infected primary human MDM.\
(**A**) Upper panel, diagram of HIV genome encoding the mutations N230D and N339E (indicated in red) to prevent N-linked glycosylation at those sites. Lower panel, diagram of HIV 89.6 N230D N339E mutant Env protein. Branched symbols represent N-linked glycans. (**B**) Summary graph showing virion release from 293Ts transfected with the indicated HIV construct as measured by p24 ELISA. (*n* = 3 experimental replicates). Statistical significance was determined by one-way ANOVA. (**C**) Western blot analysis of 293T transfected as in B. (**D**) Summary graph showing relative infection frequency of MOLT4-R5 T cells by the indicated HIV following treatment as indicated with the neutralizing antibody 2G12. The percentage of infected cells was measured by intracellular Gag stain and normalized to the untreated condition for each virus. (n = 2 independent experiments, both are plotted) (**E**) Summary graphs of relative infection of the indicated cell type by mutant or parental wild-type HIV. The frequency of infected cells was measured flow cytometrically by intracellular Gag stain and normalized to the wild-type virus. (*n* = 5 experimental replicates for MOLT4-R5; *n* = 2 experimental replicates for MDM from four independent donors). (**F**) Summary graph depicting relative infection of the indicated cell type by each virus plus or minus increasing concentrations of mannan as indicated. The frequency of infected cells was measured by intracellular Gag stain and normalized to the uninhibited (0 mg/mL mannan) condition for each virus. 89.6 pVSV-G indicates 89.6 ∆env pseudotyped with VSV-G protein. (*n* = 2 independent donors for 89.6 wild-type and 89.6 ∆env pVSV-G; *n* = 1 donor for 89.6 *env* N230D N339E) (**G**) Summary graph of virion release from primary human MDM following 10 days of infection by the indicated HIV as measured by p24 ELISA. Virion release was normalized to the infection frequency assessed flow cytometrically by intracellular Gag stain. The result for each *vpr*-null mutant was normalized to the *vpr*-competent virus encoding the same *env*. (*n* = 6 independent donors) (**H**) Summary graph of virion release from primary human MDM following 10 days of infection by the indicated HIV as measured by p24 ELISA. Virion release was normalized to the infection frequency assessed flow cytometrically by intracellular Gag stain. For this single round infection assay, all viruses were pseudotyped with YU2 Env and viral spread was blocked 48 hr later by addition of AMD3100 and maraviroc. (*n* = 8 independent donors) The result for each *vpr*-null or *vpr-nef*-null mutant was normalized to the *vpr*- and *nef*-competent virus encoding the same *env*. (**I**) Western blot analysis of MDM infected as in G. The lysates from the *vpr*-competent and *nef*-competent infections were diluted to facilitate comparisons to *vpr*- and *nef*-null mutants. (*n* = 2 independent donors) For summary graphs, the mean +/- standard deviation is shown. In panels E, G and H statistical significance was determined by a two-tailed, paired *t*-test \*p=0.01, \*\*p\<0.01, \*\*\*p\<0.001.](elife-51035-fig6){#fig6}

To confirm that mutation of N230 and N339 disrupted the mannose patch on Env, we assayed the ability of 2G12, which recognizes epitopes in the mannose patch ([@bib63]; [@bib64]) to neutralize wild-type and mutant Env. As shown in [Figure 6D](#fig6){ref-type="fig"}, wild-type but not mannose deficient N230D N339E Env was neutralized by 2G12. In addition, we found that these substitutions did not disrupt infection of a T cell line that does not express MR ([Figure 6E](#fig6){ref-type="fig"}). However, somewhat unexpectedly, we found that HIV containing the N230D N339E Env substitutions was approximately 40% less infectious to primary human macrophages expressing MR than the wild-type parental virus ([Figure 6E](#fig6){ref-type="fig"}, p=0.002). This macrophage-specific difference in infectivity suggested that mannose on Env may facilitate initial infection through interactions with MR, which is highly expressed on differentiated macrophages. To examine this possibility further, we asked whether soluble mannan, which competitively inhibits MR interactions with mannose containing glycans ([@bib67]), was inhibitory to HIV infection of macrophages. As a negative control, we tested 89.6 ∆env pseudotyped with vesicular stomatitis virus G-protein Env (VSV-G) which has only two N-linked glycosylation sites, both of which contain complex-type rather than high-mannose glycans ([@bib60]). Therefore VSV-G should not bind MR or be inhibited by mannan. As expected, we found that infection of a T cell line lacking MR was not sensitive to mannan ([Figure 6F](#fig6){ref-type="fig"}, left panel). However, infection of MDM by wild-type HIV-1 was inhibited up to 16-fold by mannan ([Figure 6F](#fig6){ref-type="fig"}, right panel). This was specific to HIV Env because mannan did not inhibit infection by HIV lacking *env* and pseudotyped with heterologous VSV-G Env. Interestingly, mannan also inhibited baseline macrophage infection by mannose-deficient Env (89.6 Env N230D N339E), indicating that N230D N339E substitutions did not completely abrogate glycans on Env that are beneficial to initial infection. In sum, our results demonstrate that interactions with mannose binding receptors are advantageous for initial HIV infection of macrophages and that the glycans remaining on Env N230D N339E retain some ability to bind glycan receptors on macrophages that facilitate infection.

While interactions between high-mannose residues on Env and MR were advantageous for viral entry, we hypothesized that they interfered with intracellular Env trafficking and were deleterious to egress of Env-containing virions in the absence of Vpr and/or Nef. To test this, we examined virion release and Env expression by HIVs encoding the mannose-deficient Env N230D N339E in the presence or absence of Vpr. In a spreading infection of MDM, we found that virus expressing mannose-deficient Env had a reduced requirement for Vpr for maximal virus release compared with the parental wild-type virus ([Figure 6G](#fig6){ref-type="fig"}, p\<0.001). In addition, in single-round infections of MDM, the mannose-deficient Env had a reduced requirement for both Nef and Vpr ([Figure 6H](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, p\<0.001). Single round infection assays cultured for ten days were used to assess the *vpr-nef* double mutant because depletion of mannose on Env did not rescue spread under conditions that were most comparable to our ten day spreading infections. The defect in spread is likely due to pleiotropic effects of Nef that disrupt interference by the HIV receptors, CD4, CXCR4 and CCR5 ([@bib37]; [@bib53]; [@bib78]) combined with the reduced infectivity of the mannose deficient Env.

Finally, we asked whether the mannose-deficient Env had increased stability in primary human MDM lacking Vpr and/or Nef by western blot analysis. We found that the Env mutant (N230D. N339E) was more stable in the absence of Vpr ([Figure 6I](#fig6){ref-type="fig"}, right side, black bars) and Nef ([Figure 6I](#fig6){ref-type="fig"}, right side, gray bars) once differences in infection frequency were accounted for by matching pr55 expression in the dilution series. These data provide strong support for a model in which MR restricts Env expression via direct interaction with high-mannose residues on Env and this restriction is counteracted by Vpr and Nef.

Silencing MR alleviates restriction of Env in primary human MDM lacking Vpr {#s2-7}
---------------------------------------------------------------------------

To directly test the hypothesis that MR is a restriction factor in MDM that is counteracted by Vpr, we examined the effect of MR silencing on Env expression in HIV-infected MDM lacking Vpr. Consistent with our hypothesis, we observed that silencing MR stabilized Env relative to Gag pr55 ([Figure 7A](#fig7){ref-type="fig"}). These results support the conclusion that the Env restriction observed in the absence of Vpr is dependent on expression of MR.

![Knockdown of MR enhances Env expression and spread to T cells in *vpr*-null infection of MDM.\
(**A**) Western blot analysis of MDM from two independent donors treated with the indicated silencing vector and infected with the indicated HIV for 10 days. The shRNA sequences encoded by the negative control vector (shNC) and the MR silencing vector (shMR) are described in Methods. (**B**) Schematic diagram of experimental protocol used for silencing experiments. (**C**) Representative flow cytometric plots showing frequency of infected (Gag^+^) primary T cells following two days of co-culture with autologous, HIV 89.6 infected primary MDM. T cells were identified in co-culture by gating on CD3^+^ CD14^-^ cells as shown in [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}. (**D**) Summary graph displaying relative infection of MDM and T cells as measured in C (*n* = 5 independent donors). Data in the left panel are unnormalized. In the right panel the data have been normalized to the wild-type condition for each donor and shRNA.](elife-51035-fig7){#fig7}

Previous work in our laboratory demonstrated that restriction of Env in primary human MDM disrupted formation of virological synapses and cell-to-cell spread of HIV from infected MDM to T cells ([@bib15]). Expression of Vpr alleviated these effects, dramatically increasing viral transmission -- especially under conditions of low initial inoculum of free virus. To expand on these findings, we measured Vpr-dependent HIV-1 spread from primary human MDM to autologous T cells, as diagrammed in [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}. Co-cultured cells were stained for CD3 to distinguish T cells and CD14 to distinguish MDM as shown in [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}, accounting for differences in autofluorescent background in the two cell types by using isotype controls ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}) We confirmed our prior finding that Vpr enhances HIV-1 89.6 spread from MDM to T cells ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}) and extended this finding to the transmitted/founder (T/F) clone REJO ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). Consistent with our previous findings, we observed that a higher frequency of T cells became infected following co-culture with infected MDM as compared to incubation with high titer cell free virus \[47-fold (89.6, p=0.0002) and 38-fold (REJO, p=0.048)\].

To determine whether Vpr stimulated spread from macrophages to T cells by counteracting MR restriction, we measured spread to T cells from macrophages in which MR had been silenced as diagrammed in [Figure 7B](#fig7){ref-type="fig"}. Using the gating strategy shown in [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}, infected MDM and infected T cells were identified by intracellular Gag stain ([Figure 7C](#fig7){ref-type="fig"}). We found that silencing MR reduced the difference between wild type and Vpr-null infected macrophage spread to T cells from 7-fold (p=0.003) to 2-fold (p=0.02) ([Figure 7D](#fig7){ref-type="fig"}). These results provide strong evidence that MR is the previously described but unidentified restriction factor in macrophages that reduces HIV spread from macrophages to T lymphocytes in the absence of Vpr.

Discussion {#s3}
==========

We previously reported that Env and Env-containing virions are degraded in macrophage lysosomes in the absence of Vpr, impairing virion release, virological synapse formation, and spread of HIV to T cells ([@bib48]; [@bib15]). Moreover, this requirement for Vpr was conferred to heterokaryons comprised of macrophages and permissive cells, suggesting the existence of a previously unidentified host restriction factor that is counteracted by Vpr in macrophages ([@bib48]). Results presented here clearly define mannose receptor (MR) as the HIV restriction factor counteracted by Vpr in macrophages to enhance viral dissemination. We provide strong evidence that Env mannosylation is required for restriction of Env and virion release in macrophages in the absence of Vpr, and that MR silencing relieves a requirement for Vpr to overcome this restriction. Moreover, we confirm and extend a prior report that Nef also acts to downmodulate MR from the macrophage cell surface ([@bib79]) and demonstrate that Vpr and Nef cooperate to counteract MR in an additive fashion through independent mechanisms.

Other investigators have reported that HIV inhibits *MRC1* transcription in macrophages and that MR inhibits virion egress upon exogenous expression in 293T cells ([@bib73]). In contrast to results we report here, the prior study observed effects on virions that were Env-independent and did not examine effects of Vpr on MR. In primary macrophages, Vpr-sensitive virion restriction only occurs when virions contain Env ([@bib48]) and genetic changes in the *env* open reading frame -- especially those that alter N-linked glycosylation sites -- critically affect the requirement for Vpr. The effect of MR on Env and Env-containing virion release reported here helps explain previous observations that primate lentivirus infection reduces MR activity in humans ([@bib32]; [@bib33]) and monkeys ([@bib29]). By confirming and extending our prior finding that Vpr-mediated stabilization of Env promotes macrophage to T cell spread ([@bib15]) we also provide an explanation for how Vpr increases infection of human lymphoid tissue ex vivo ([@bib20]; [@bib62]), which contain macrophages and T cells in a highly physiological, three-dimensional environment.

As Nef had already been shown to reduce MR surface expression ([@bib79]), the observation that HIV encodes a second protein, Vpr, to reduce MR expression was unanticipated, but not unprecedented; other host proteins are known to be affected by more than one lentiviral accessory protein. The HIV receptor, CD4, is simultaneously targeted by Vpu, Nef and Env in HIV-1 ([@bib12]) and tetherin is alternately targeted by Vpu, Nef, or Env in different strains of primate lentiviruses ([@bib25]). Nef has also been shown to downmodulate the viral co-receptors CXCR4 ([@bib78]) and CCR5 ([@bib53]), which may also interfere with Env expression and viral egress in infected cells. Nef's activity against CXCR4, CCR5, and MR presumably has the same ultimate purpose as its activity against CD4, namely to stabilize Env, enhance virion release and prevent superinfection of the producer cell ([@bib37]; [@bib61]). The impact of these deleterious interactions is clearly demonstrated by the profound loss of Env we observed in HIV-infected macrophages lacking both Vpr and Nef.

The need for both Vpr and Nef to counteract MR may be explained by the high level of MR expression, estimated at 100,000 copies per macrophage ([@bib69]). The potent combined effect likely derives from synergistic targeting of MR at two different stages of MR synthesis. Nef was shown to alter MR trafficking ([@bib79]) and we show Vpr inhibits MR transcription.

In addition, our results suggest that maximal MR downmodulation is time-dependent in macrophages, which have the capacity to survive while infected for weeks; western blot analysis of whole cell lysates from saturated, ten-day infected cultures achieved a more striking reduction than was observed by flow cytometric analysis of five day cultures of macrophages infected with non-spreading viruses expressing GFP. This time dependency is potentially explainable in part by the very long half-life of MR \[33 hr ([@bib39])\] combined with the large amount of MR expressed per cell discussed above.

In sharp contrast to the effect we observed in MDM, Vpr did not affect MR protein levels when MR was expressed via a heterologous promoter in the 293T cell line, which is derived from human embryonic kidney cells and is not a natural target of HIV. The cell type selectivity in these experiments is likely due to differences in the promoters driving MR expression, however, we cannot rule out the existence of other macrophage specific pathways required to recreate the effect of Vpr on MR. Further work will be needed to examine these questions and determine other mechanistic details.

Our findings also implicate the Vpr binding protein VprBP/DCAF1 ([@bib50]), a component of the cellular DCAF1-DDB1-CUL4 E3 ubiquitin ligase complex, in downmodulation of MR by Vpr. This complex is required for most of the known functions of Vpr, including: disruption of the cell cycle, disruption of cellular DNA repair pathways in dividing cells ([@bib7]; [@bib30]; [@bib38]; [@bib80]; [@bib35]; [@bib81]; [@bib83]) and transcriptional inhibition of type I interferons in response to infection in macrophage cultures ([@bib34]; [@bib48]). Additional research is now needed to determine how interactions between Vpr and DCAF1 mediate these pleiotropic effects.

Deleterious interactions between MR and Env that are alleviated by Vpr and Nef, likely occur along the secretory pathway and continue at the cell surface. This is based on previously published work showing that Env-containing virions are retained at the cell surface and targeted to lysosomes in macrophages lacking Vpr ([@bib15]). Our prior studies also provided evidence that unprocessed Env gp160 is affected and targeted to lysosomal compartments albeit to a lesser degree ([@bib48]). Because Env processing occurs via furin-mediated cleavage in the trans-Golgi network (TGN), the effect on unprocessed Env provides evidence that in addition to acting at the surface, MR likely also interacts with Env along the secretory pathway prior to its arrival and processing in the TGN.

MR's interaction with Env appears to be mediated by the unusually high density of N linked glycosylation sites on Env that retain high-mannose glycans, which is a known pathogen-associated molecular pattern ([@bib70]; [@bib51]). Here, we show that selective deletion of mannose residues alleviated the requirement for Vpr. Deletion of individual glycosylation sites is known to lead to changes in the processing of neighboring glycans and deletions at certain sites lead to larger than expected losses of oligomannose ([@bib6]) presumably because their removal allows greater access to mannosidases and facilitates trimming of surrounding glycans. Selective pressure to maintain mannose residues on Env may be due to the enhanced attachment they mediate. Indeed, we provide strong evidence that Env's interaction with MR boosts initial infection of MDM. This finding is supported by a prior report that MR enhances HIV-1 binding to macrophages and transmission of the bound virus to co-cultured T cells ([@bib55]). Our study adds to these findings by providing evidence that interactions with mannose binding receptors also enhance direct infection of macrophages. Moreover, the capacity of Vpr and Nef to mitigate the effect of detrimental intracellular interactions during viral egress limits the negative impact of retaining high-mannose on Env. In addition, the dense glycan packing, which is privileged from antibody recognition through immune tolerance, is believed to play a role in evasion of the antibody response ([@bib71]).

Because MR has both positive and negative effects on infection, the interpretation of some experiments examining spreading infection in the setting of MR silencing or mutations in Env that reduced mannose content were complex to interpret. Some donors had increased infection resulting from MR silencing whereas others had a small decrease at the ten-day time point (data not shown). By using viral systems that allowed us to focus independently on viral entry and exit, we nevertheless clearly discerned that MR can serve as a positive factor for entry and a negative factor for egress.

Thus far, all viral Envs we have tested (NL4-3, AD8 and 89.6) require Vpr for stable expression in macrophages except YU-2. We show here that genetically altering the mannose patch on 89.6 so that it mirrored changes in the YU-2 mannose patch altered the behavior of 89.6 to resemble that of YU-2 with respect to Vpr phenotypes. This is strong evidence supporting our model that Vpr alleviates deleterious interactions caused by the Env mannose patch. Interestingly, YU-2 was cloned from the central nervous system and 89.6 was directly cloned from peripheral blood. Because the blood-brain barrier limits exposure to antibodies, CNS isolates may have a diminished requirement for high mannose residues, which protect from antibody responses.

Here we also confirm and extend our prior observation ([@bib15]) that co-culturing T cells with infected MDM boosted HIV infection compared to direct infection of T cells with cell-free virus. Similar to clone 89.6, T cell infection by the transmitter/founder virus REJO was enhanced by co-culture with MDM, and spread from MDM to T cells was enhanced by Vpr. In the context of natural person-to-person transmission, accelerated spread to T cells may be critical to establishing a persistent infection before innate and adaptive immune responses are activated. The strong selective pressure to retain Vpr despite its limited effect on T cell-only cultures indicates there is more to learn about the role of Vpr, macrophages and T/F viruses in HIV transmission and pathogenesis. Collectively, these studies suggest that novel therapeutic approaches to inhibit the activity of Vpr and Nef in macrophages would potentially represent a new class of antiretroviral drug that could be an important part of a treatment or prophylactic cocktail.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                        Designation                                        Source or\                                                                Identifiers                      Additional\
  (species)                                                                               reference                                                                                                  \
                                                                                                                                                                                                     Information
  ------------------------------------ -------------------------------------------------- ------------------------------------------------------------------------- -------------------------------- ---------------------------------------------------------------------------------------------------------------------
  Recombinant DNA reagent              p89.6                                              [@bib16] PMID: [1433527](https://www.ncbi.nlm.nih.gov/pubmed/1433527)     NIH AIDS Reagent Program 3552    

  Recombinant DNA reagent              p89.6 vpr-null                                     [@bib48]; PMID [25464830](https://www.ncbi.nlm.nih.gov/pubmed/25464830)                                    

  Recombinant DNA reagent              p89.6 nef-null                                     [@bib11]; PMID [20208541](https://www.ncbi.nlm.nih.gov/pubmed/20208541)                                    

  Recombinant DNA reagent              p89.6 vpr-nef-null                                 this paper                                                                                                 Produces HIV 89.6 vpr-nef-null double mutant

  Recombinant DNA reagent              p89.6 env N230D N339E                              this paper                                                                                                 Produces HIV 89.6 env N230D N339E mutant

  Recombinant DNA reagent              p89.6 env N230D N339E vpr-null                     this paper                                                                                                 Produces HIV 89.6 env N230D N339E vpr-null mutant

  Recombinant DNA reagent              p89.6 env N230D N339E vpr-nef-null                 this paper                                                                                                 Produces HIV 89.6 env N230D N339E vpr-nef-null mutant

  Recombinant DNA reagent              pNL4-3                                             [@bib2]; PMID [3016298](https://www.ncbi.nlm.nih.gov/pubmed/3016298)      NIH AIDS Reagent Program 114     

  Recombinant DNA reagent              pNL4-3 env^YU2^                                    this paper                                                                                                 Produces HIV NL4-3 env^YU2^ chimera

  Recombinant DNA reagent              pNL4-3 env^YU2^vpr-null                            this paper                                                                                                 Produces HIV NL4-3 env^YU2^vpr-null chimera

  Recombinant DNA reagent              pHCMV-G                                            ATCC                                                                      75497                            Expresses VSV-G

  Recombinant DNA reagent              pCMV-HIV-1                                         [@bib23]; PMID [9971760](https://www.ncbi.nlm.nih.gov/pubmed/9971760)                                      Expresses HIV structural proteins

  Recombinant DNA reagent              pNL4-3 ∆GPE-GFP                                    [@bib52]; PMID [22718820](https://www.ncbi.nlm.nih.gov/pubmed/22718820)                                    

  Recombinant DNA reagent              pNL4-3 ∆GPE-GFP vpr-null                           this paper                                                                                                 Produces NL4-3 ∆GPE vpr-null

  Recombinant DNA reagent              pNL4-3 ∆GPE-GFP vpr-Q65R                           this paper                                                                                                 Produces NL4-3 ∆GPE vpr-Q65R

  Recombinant DNA reagent              pNL4-3 ∆GPE-GFP nef-null                           this paper                                                                                                 Produces NL4-3 ∆GPE nef-null

  Recombinant DNA reagent              pNL4-3 ∆GPE-GFP vpr-nef-null                       this paper                                                                                                 Produces NL4-3 ∆GPE vpr-nef-null

  Recombinant DNA reagent              pYU2                                               [@bib42]; PMID [1830110](https://www.ncbi.nlm.nih.gov/pubmed/1830110)     NIH AIDS Reagent Program 1350    

  Recombinant DNA reagent              pYU2 vpr-null                                      this paper                                                                                                 Produces YU-2 vpr-null

  Recombinant DNA reagent              pREJO.c/2864                                       [@bib57]; PMID [22190722](https://www.ncbi.nlm.nih.gov/pubmed/22190722)   NIH AIDS Reagent Program 11746   

  Recombinant DNA reagent              pREJO.c/2864 vpr-null                              this paper                                                                                                 Produces REJO vpr-null

  Recombinant DNA reagent              pSIV3+                                             [@bib58]; PMID [21696578](https://www.ncbi.nlm.nih.gov/pubmed/21696578)                                    

  Recombinant DNA reagent              pSIV3+ vpr-null                                    this paper                                                                                                 Produces SIV3+ vpr-null

  Recombinant DNA reagent              pSPAX2                                             [@bib58]; PMID [21696578](https://www.ncbi.nlm.nih.gov/pubmed/21696578)                                    

  Recombinant DNA reagent              pAPM-1221                                          [@bib58]; PMID [21696578](https://www.ncbi.nlm.nih.gov/pubmed/21696578)                                    Silences luciferase mRNA

  Recombinant DNA reagent              pAPM-MRC1-C                                        this paper                                                                                                 Silences MR mRNA

  Recombinant DNA reagent              pMD2.G                                             [@bib58]; PMID [21696578](https://www.ncbi.nlm.nih.gov/pubmed/21696578)                                    Expresses VSV-G

  Recombinant DNA reagent              pYU2 env                                           [@bib74]; PMID [7769703](https://www.ncbi.nlm.nih.gov/pubmed/7769703)                                      

  Recombinant DNA reagent              pCDNA3.hMR                                         [@bib45]; PMID [15047828](https://www.ncbi.nlm.nih.gov/pubmed/15047828)                                    Expresses MR

  Recombinant DNA reagent              pPROA-3FLAG-UNG2-EYFP                              [@bib4]; PMID [20466601](https://www.ncbi.nlm.nih.gov/pubmed/20466601)                                     

  Recombinant DNA reagent              pMSCV IRES-GFP                                     [@bib77]; PMID [10514006](https://www.ncbi.nlm.nih.gov/pubmed/10514006)                                    

  Recombinant DNA reagent              pMSCV 3xFLAG UNG2 IRES-GFP                         this paper                                                                                                 Expresses 3x FLAG-tagged UNG2

  Recombinant DNA reagent              pUC19                                              [@bib56]; PMID [6323249](https://www.ncbi.nlm.nih.gov/pubmed/6323249)                                      

  Chemical compound, drug              Ficoll-Paque Plus                                  GE Healthcare                                                             17-1440-02                       

  Chemical compound, drug              rhM-CSF                                            R and D Systems                                                           216-MC-025/CF                    

  Chemical compound, drug              rhGM-CSF                                           R&D Systems                                                               215 GM-050                       

  Chemical compound, drug              IL-2                                               R&D Systems                                                               202-IL-010                       

  Chemical compound, drug              phytohaemagglutinin-L                              Calbiohem                                                                 431784                           

  Chemical compound, drug              Enzyme-free cell dissociation buffer, HBSS-based   ThermoFisher                                                              13150016                         

  Chemical compound, drug              Blue loading buffer                                Cell Signaling Technology                                                 7722                             

  Chemical compound, drug              AMD3100                                            [@bib27]; PMID [10817726](https://www.ncbi.nlm.nih.gov/pubmed/10817726)   NIH AIDS Reagent Program 8128    

  Chemical compound, drug              Maraviroc                                          [@bib21]; PMID [17933722](https://www.ncbi.nlm.nih.gov/pubmed/17933722)   NIH AIDS Reagent Program 11580   

  Chemical compound, drug              streptavidin-HRP                                   Fitzgerald                                                                65R-S104PHRP                     

  Chemical compound, drug              3,3\',5,5\'-tetramethylbenzidine                   Sigma                                                                     T8665-IL                         

  Chemical compound, drug              Gag p24 standard                                   ViroGen                                                                   00177 V                          

  Chemical compound, drug              Protein G Column                                   GE Healthcare                                                             45-000-054                       

  Commercial assay, kit                Q5 site-directed mutagenesis kit                   New England Biolabs                                                       E0554S                           

  Commercial assay, kit                EasySep Human CD14 Positive Selection Kit II       Stemcell Technologies                                                     17858                            

  Commercial assay, kit                CD8 Dynabeads                                      ThermoFisher                                                              11147D                           

  Commercial assay, kit                RNeasy micro RNA isolation kit                     Qiagen                                                                    74004                            

  Commercial assay, kit                qScript cDNA Supermix                              Quantabio                                                                 95048                            

  Commercial assay, kit                TaqMan Gene Expression Master Mix                  ThermoFisher                                                              4369016                          

  Commercial assay, kit                EZ-link Micro Sulfo-NHS-Biotinylation kit          ThermoFisher                                                              PI-21925                         

  Sequence-based reagent               896 dNef-F                                         this paper                                                                PCR primer                       CACCATTATCGTTTCAGACCCT

  Sequence-based reagent               896 dNef-R                                         this paper                                                                PCR primer                       TCTCGAGTTTAAACTTAT AGCAAAGCCCTTTCCA

  Sequence-based reagent               NL43 vprQ65R-Forward                               this paper                                                                PCR primer                       AGAATTCTGCGACAACTGCTG

  Sequence-based reagent               NL43 vprQ65R-Reverse                               this paper                                                                PCR primer                       TATTATGGCTTCCACTCC

  Sequence-based reagent               3xFLAG UNG2 F                                      this paper                                                                PCR primer                       CTAGCTCGAGACCATGGACT ACAAAGACCATGAC

  Sequence-based reagent               3xFLAG UNG2 R                                      this paper                                                                PCR primer                       GTTAACTCACAGCTCCTTC CAGTCAATGGGCTT

  Sequence-based reagent               GeneExpression assay for ACTB                      ThermoFisher                                                              Hs99999903                       

  Sequence-based reagent               GeneExpression assay for MRC1                      ThermoFisher                                                              Hs00267207                       

  Sequence-based reagent               GeneExpression assay for POL2A                     ThermoFisher                                                              Hs02786624                       

  Sequence-based reagent               GeneExpression assay for GAPDH                     ThermoFisher                                                              Hs00172187                       

  Sequence-based reagent               APM-MRC1-C Forward oligo                           Sigma                                                                     DNA oligo                        TCGAGAAGGTATATTGCT GTTGACAGTGAGCGAGTA ACTTGACTGATAATCAATT AGTGAAGCCACAGATGTA ATTGATTATCAGTCAAGTT ACTTGCCTACTGCCTCGG

  Sequence-based reagent               APM-MRC1-C Reverse oligo                           Sigma                                                                     DNA oligo                        AATTCCGAGGCAGTAGGC AAGTAACTTGACTGATAA TCAATTACATCTGTGGCT TCACTAATTGATTATCAG TCAAGTTACTCGCTCACT GTCAACAGCAATATACCTTC

  Biological sample (*Homo sapiens*)   Buffy coats/LeukoPaks                              New York Blood Center                                                                                      Buffy coats made from whole blood

  Biological sample (adenovirus)       Adeno-nef                                          [@bib41]; PMID [21543478](https://www.ncbi.nlm.nih.gov/pubmed/21543478)                                    

  Cell line (*Homo sapiens*)           HEK293T                                            ATCC                                                                      CRL-3216                         

  Cell line (*Mus musculus*)           anti-gp41 hybridoma CHESSIE-8                      [@bib1]; PMID [8068416](https://www.ncbi.nlm.nih.gov/pubmed/8068416)      NIH AIDS Reagent Program 526     Purified ab used for WB (2 µg/mL)

  Cell line (*Mus musculus*)           anti-p24 hybridoma 183-H12-5C                      NIH AIDS Reagent Program                                                  1513                             Purified ab used for ELISA (1 µg/mL)

  Cell line (*Mus musculus*)           anti-p24 hybridoma 31-90-25                        ATCC (discontinued)                                                       HB-9725                          Purified ab used for ELISA (0.5 µg/mL)

  Antibody                             anti-mannose receptor-PE (mouse monoclonal)        Becton Dickinson                                                          clone 19.2 cat\# 555954          FC (1 µL per test)

  Antibody                             anti-Gag CA p24-PE (mouse monoclonal)              Beckman Coulter                                                           clone KC57 cat\# 6604667         FC (0.25 µL per test)

  Antibody                             anti-Gag CA p24-FITC (mouse monoclonal)            Beckman Coulter                                                           clone KC57 cat\# 6604665         FC (0.25 µL per test)

  Antibody                             anti-FLAG (mouse monoclonal)                       Sigma                                                                     clone M2 cat\# F3165             FC (1 µL per test), WB (1:1000)

  Antibody                             anti-CD4-APC (mouse monoclonal)                    ThermoFisher                                                              clone OKT4 cat\# 17-0048-42      FC (1 µL per test)

  Antibody                             anti-CD3-PacBlue (mouse monoclonal)                BioLegend                                                                 clone OKT3 cat\# 317313          FC (1 µL per test)

  Antibody                             anti-CD14-APC (mouse monoclonal)                   BioLegend                                                                 clone HCD14 cat\# 325608         FC (1 µL per test)

  Antibody                             anti-mannose receptor (rabbit polyclonal)          Abcam                                                                     ab64693                          WB (1:1000)

  Antibody                             anti-rabbit-AF647 (goat polyclonal)                ThermoFisher                                                              A21244                           WB (1:4000)

  Antibody                             anti-GAPDH (mouse monoclonal)                      Abnova                                                                    clone 3C2 cat\# H00002597-M01    WB (1:2000)

  Antibody                             anti-mouse IgG1-AF647 (goat polyclonal)            ThermoFisher                                                              A21240                           FC (1 µL per test), WB (1:4000)

  Antibody                             HIV-Ig (human polyclonal)                          [@bib19]; PMID [1995097](https://www.ncbi.nlm.nih.gov/pubmed/1995097)     NIH AIDS Reagent Program 3957    WB (1:2000)

  Antibody                             anti-human-AF647 (goat polyclonal)                 ThermoFisher                                                              A21445                           WB (1:4000)

  Antibody                             anti-gp120 (sheep polyclonal)                      [@bib26]; PMID [1374448](https://www.ncbi.nlm.nih.gov/pubmed/1374448)     NIH AIDS Reagent Program 288     WB (1:1000)

  Antibody                             anti-sheep-HRP (rabbit polyclonal)                 Dako                                                                      P0163                            WB (1:20,000)

  Antibody                             anti-gp41 (human monoclonal)                       [@bib84]; PMID [11602729](https://www.ncbi.nlm.nih.gov/pubmed/11602729)   NIH AIDS Reagent Program 11557   WB (1:1000)

  Antibody                             anti-human (goat polyclonal)                       ThermoFisher                                                              62--8420                         WB (1:10,000)

  Antibody                             anti-Nef (rabbit polyclonal)                       [@bib68]; PMID [8043040](https://www.ncbi.nlm.nih.gov/pubmed/8043040)     NIH AIDS Reagent Program 2949    WB (1:1000)

  Antibody                             anti-Vpr (rabbit polyclonal)                       Dr. Jeffrey Kopp                                                          NIH AIDS Reagent Program 11836   WB (1:1000)

  Antibody                             anti-rabbit (goat polyclonal)                      ThermoFisher                                                              65--6120                         WB (1:10,000)

  Antibody                             anti-GFP (chicken polyclonal)                      Abcam                                                                     ab13970                          WB (1:1000)

  Antibody                             anti-chicken-HRP (goat polyclonal)                 ThermoFisher                                                              A16054                           WB (1:10,000)

  Antibody                             anti-STING (rabbit monoclonal)                     Cell Signaling Technology                                                 clone D2P2F cat\# 13647          WB (1:500)

  Antibody                             anti-GBP5 (goat polyclonal)                        Dr. Frank Kicrhhoff                                                       sc-160353                        WB (1:500)

  Antibody                             anti-IFITM3 (rabbit polyclonal)                    Proteintech                                                               11714--1-AP                      WB (1:1000)

  Antibody                             anti-Env 2G12 (human monoclonal)                   [@bib9]; PMID [7520721](https://www.ncbi.nlm.nih.gov/pubmed/7520721)      NIH AIDS Reagent Program 1476    neutralization (1 µg/mL)

  Software, algorithm                  FlowJo 10                                          BD                                                                        10.6.1                           

  Software, algorithm                  ABI Sequence Detection Software                    ThermoFisher                                                              1.4                              

  Software, algorithm                  ImageQuant TL                                      GE                                                                        8.2.0                            

  Software, algorithm                  Photoshop CC                                       Adobe                                                                     20.0.6                           

  Software, algorithm                  shRNA retriever                                    <http://katahdin.mssm.edu/siRNA/RNAi.cgi?type=shRNA>                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Viruses, viral vectors, and expression plasmids {#s4-1}
-----------------------------------------------

The following molecular clones were obtained via the AIDS Reagent Program: p89.6 \[cat\# 3552 from Dr. Ronald G. Collman), pNL4-3 (cat\# 114 from Dr. Malcolm Martin), pREJO.c/2864 (cat\# 11746 from Dr. John Kappes and Dr. Christina Ochsenbauer) and pYU2 (cat\# 1350 from Dr. Beatrice Hahn and Dr. George Shaw). *Vpr*-null versions of 89.6, NL4-3, and YU2 were created by cutting the AflII site within *vpr* and filling in with Klenow fragment. The *vpr*-null version of REJO was created by doing the same at the AvrII site. A *nef*-null version of 89.6 was created by deleting *nef* from its start codon to the XhoI site. To do this, a PCR amplicon was generated from the XhoI site in *env* to *env*'s stop codon. The 3' reverse primer added a XhoI site after the stop codon. The 89.6 genome and the amplicon were digested with XhoI and ligated together. (5' primer CACCATTATCGTTTCAGACCCT and 3' primer TCTCGAGTTTAAACTTATAGCAAAGCCCTTTCCA). The NL4-3 env^YU2^ chimera consists of the pNL4-3 plasmid in which the fragment from the KpnI site in *env* to the BamHI site in *env* has been replaced with the equivalent fragment of pYU-2. Because the KpnI site is not unique within the plasmid, the fragment from the SalI site to BamHI site (which are unique) was cloned into pUC19, the change was made in *env*, and the fragment from SalI to BamHI was inserted back into pNL4-3. To generate p89.6 N230D N339E a synthetic DNA sequence (ThermoFisher, Waltham, Massachusetts) was purchased commercially. The synthetic gene contained the following nucleotide mutations, counting from the start of 89.6 *env*: 694 A \> G, 701 C \> A, 1018 A \> G, 1020 T \> A. This sequence was substituted into p89.6 using the KpnI and BsaBI sites within *env*. pSIV3+, pSPAX2, pAPM-1221 and pMD2.G were obtained from Dr. Jeremy Luban ([@bib58]). pSIV3+ *vpr*-null was generated using a synthesized DNA sequence (ThermoFisher) containing a fragment of the SIV genome in which the Vpr start codon was converted to a stop codon (TAG). This was substituted into pSIV3+ using the sites BstBI and SapI. pYU2 env was obtained from Dr. Joseph Sodroski ([@bib74]). Creation of pNL4-3 ∆GPE-GFP was described previously ([@bib82]; [@bib52]). Notably, the transcript containing the *gfp* gene retains the first 42 amino acids of *env*, including the signal peptide, which creates a fully fluorescent Env-GFP fusion protein. The *vpr*-Q65R mutant of NL4-3 ∆GPE-GFP was created using the Q5 site-directed mutagenesis kit from New England Biolabs (Ipswich, MA). The forward primer was AGAATTCTGCGACAACTGCTG and the reverse primer TATTATGGCTTCCACTCC. After synthesis by PCR, the entire provirus was confirmed by sequencing.

pCDNA.3.hMR was obtained from Dr. Johnny J. He ([@bib45]). pPROA-3FLAG-UNG2-EYFP was obtained from Dr. Marit Otterlei ([@bib4]) and 3x FLAG tagged UNG2 was amplified using the 5' primer CTAGCTCGAGACCATGGACTACAAAGACCATGAC, which added an XhoI site, and the 3' primer GTTAACTCACAGCTCCTTCCAGTCAATGGGCTT, which added an HpaI site. The amplicon was cloned into the XhoI and HpaI sites of pMSCV IRES-GFP ([@bib77]) to generate pMSCV 3xFLAG UNG2 IRES-GFP.

Primary MDM and T cell isolation and culture {#s4-2}
--------------------------------------------

Leukocytes isolated from anonymous donors by apheresis were obtained from the New York Blood Center Component Laboratory. The use of human blood from anonymous, de-identified donors was classified as non-human subject research in accordance with federal regulations and thus not subjected to formal IRB review. Peripheral blood mononuclear cells (PBMCs) were purified by Ficoll density gradient. CD14^+^ monocytes were positively selected using a CD14 sorting kit (cat\# 17858, StemCell Technologies, Vancouver, Canada) following the manufacturer's instructions. Monocyte-derived macrophages (MDM) were obtained by culturing monocytes in R10 \[RPMI-1640 with 10% certified endotoxin-low fetal bovine serum (Invitrogen, ThermoFisher), penicillin (100 Units/mL), streptomycin (100 μg/mL), L-glutamine (292 μg/mL), carrier-free M-CSF (50 ng/mL, R and D Systems, Minneapolis, Minnesota) and GM-CSF (50 ng/mL, R and D Systems)\] for seven days. Monocytes were plated at 5 × 10^5^ cells/well in a 24 well dish, except for those to be transduced with lentivirus and puromycin selected, which were plated at 1 × 10^6^ cells/well.

CD4+ T lymphocytes were prepared from donor PBMCs as follows: anti-CD8 Dynabeads (cat\# 11147D, ThermoFisher) were used to deplete CD8+ T lymphocytes and the remaining cells, which were mainly CD4+ lymphocytes, were maintained in R10 until the time of stimulation. Lymphocytes were stimulated with 5 μg/mL phytohemagglutinin (PHA-L, Calbiochem, Millipore Sigma, Burlington, Massachusetts) overnight before addition of 50 IU/mL recombinant human IL-2 (R and D Systems).

Cell lines {#s4-3}
----------

The 293T cell line was obtained from ATCC and independently authenticated by STR profiling. It was maintained in DMEM medium (Gibco) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamine (Pen-Strep-Glutamine, Invitrogen), 10% fetal bovine serum (Invitrogen), and 0.022% plasmocin (Invivogen). The MOLT-R5 cell line was obtained from the NIH AIDS Reagent Repository, which confirmed the lot is mycoplasma negative. It was maintained in RPMI-1640 medium (Gibco) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM glutamine (Pen-Strep-Glutamine, Invitrogen), 10% fetal bovine serum (Invitrogen), and 0.022% plasmocin (Invivogen).

Silencing by shRNA {#s4-4}
------------------

Sequences within *MRC1* suitable for shRNA-based targeting were identified using the program available at <http://katahdin.mssm.edu/siRNA/RNAi.cgi?type=shRNA> maintained by the laboratory of Dr. Ravi Sachidanandam. The sequence chosen, 5'-AGTAACTTGACTGATAATCAAT-3' was synthesized as part of larger DNA oligonucleotides with the sequences TCGAGAAGGTATATTGCTGTTGACAGTGAGCGAGTAACTTGACTGATAATCAATTAGTGAAGCCACAGATGTAATTGATTATCAGTCAAGTTACTTGCCTACTGCCTCGG (forward) and AATTCCGAGGCAGTAGGCAAGTAACTTGACTGATAATCAATTACATCTGTGGCTTCACTAATTGATTATCAGTCAAGTTACTCGCTCACTGTCAACAGCAATATACCTTC (reverse). These oligos were annealed, which created overhangs identical to those produced by digestion with the enzymes EcoRI and XhoI. This double stranded DNA oligomer was inserted into the EcoRI and XhoI sites of pAPM-1221 to generate pAPM-MRC1-C.

Short hairpin RNA-mediated silencing was performed as previously described ([@bib58]; [@bib49]; [@bib15]). Briefly, we spinoculated freshly isolated primary monocytes with VSV-G-pseudotyped SIV3+ *vpr*-null at 2500 rpm for 2 hr with 4 μg/mL polybrene to allow Vpx-dependent degradation of SAMHD1. Cells were then incubated overnight in R10 with M-CSF (50 ng/mL) and GM-CSF (50 ng/mL) plus VSV-G-pseudotyped lentivirus containing an shRNA cassette targeting luciferase (pAPM-1221 or 'shNC') or MR (pAPM-MRC1-C or 'shMR'). The following day, media was removed and replaced with fresh R10 with M-CSF (50 ng/mL) and GM-CSF (50 ng/mL). Three days later 10 μg/mL puromycin was added and cells were cultured for three additional days prior to HIV-1 infection. shRNA target sequences used: *Luciferase*: 5\'-TACAAACGCTCTCATCGACAAG-3\', *MRC1:* 5'-ATTGATTATCAGTCAAGTTACT-3'.

Virus production {#s4-5}
----------------

Virus stocks were obtained by transfecting 293T cells (ATCC, Manassas, Virginia) with viral DNA and polyethylenimine (PEI). Cells were plated at 2.5 × 10^6^ cells per 10 cm dish and incubated overnight. The following day 12 µg of total DNA was combined with 48 µg of PEI, mixed by vortexing, and added to each plate of cells. For NL4-3 ∆GPE-GFP, cells were transfected with 4 µg viral genome, 4 µg pCMV-HIV, and 4 µg pHCMV-V (VSV-G expression plasmid). For SIV3+ *vpr*-null the cells were transfected with 10.5 µg of viral genome and 1.5 µg pHCMV-V. For shLentivirus (shNC or shMR) cells were transfected with 6 µg pAPM-1221 or pAPM-MRC1-C, 4.5 µg pSPAX2, and 1.5 µg pMD2.G. Viral supernatant was collected 48 hr post-transfection and centrifuged at 1500 rpm (500 x *g*) 5 min to remove cellular debris. SIV3+ *vpr*-null was pelleted by centrifugation at 14,000 rpm (23,700 x *g*) for 4 hr at 4°C and resuspended at 10x concentration. Virus stocks were aliquoted and stored at −80°C.

Co-transfections {#s4-6}
----------------

Co-transfections of HIV and MR or UNG2 were performed in 293T cells. Cells were plated at 1.6 × 10^5^ per well in a 12-well dish. The following day 10 ng of pcDNA.3.hMR or 10 ng of pMSCV 3xFLAG UNG2 IRES-GFP, 250 ng of NL4-3 ∆GPE-GFP, and 740 ng pUC19 plasmid was combined with 4 µg PEI, mixed by vortexing, and added to each well. 48 hr later, cells were lifted using enzyme free cell dissociation buffer (ThermoFisher, cat\# 13150016) and analyzed by flow cytometry or lysed in 500 µL blue loading buffer (cat\# 7722, Cell Signaling Technology, Danvers, Massachusetts) and analyzed by western blot.

HIV infections of MDM {#s4-7}
---------------------

Prior to infection, 500 µL of medium was removed from each well and this 'conditioned' medium was saved to be replaced after the infection. MDM were infected by equal inocula of HIV as measured by Gag p24 mass in 500 µL of R10 for 6 hr at 37°C. After 6 hr, infection medium was removed and replaced with a 1:2 mixture of conditioned medium and fresh R10. Where indicated, HIV spread was blocked by AMD3100 (10 µg/mL, AIDS Reagent Program cat\# 8128) and/or maraviroc (20 µM, AIDS Reagent Program cat\# 11580) added 48 hr post-infection and replenished with each media change every three days.

Spin transduction of MDM with NL4-3 ∆GPE-GFP {#s4-8}
--------------------------------------------

MDM were centrifuged at 2500 rpm (1049 x *g*) for 2 hr at 25°C with equal volume of NL4-3 ∆GPE-GFP or an isogenic mutant in 500 uL total medium. Following infection, medium was removed and replaced with a 1:2 mixture of conditioned medium and fresh R10.

Adenoviral transduction of MDM {#s4-9}
------------------------------

Adenovirus was prepared by the University of Michigan Vector Core, and the transduction of MDM was performed as previously described ([@bib41]) at an MOI of 1000 based on 293T cell infection estimations and the concentration of particles as assessed by OD~280~.

Infection of T cells {#s4-10}
--------------------

Activated T cells were infected by two methods as indicated. For direct infection, 5 × 10^5^ cells were plated per well with 50 µg HIV p24 in 500 µL R10 +50IU/mL of IL-2 and incubated at 37°C for 48 hr. For co-culture with autologous, infected MDM medium was removed from MDM wells and 5 × 10^5^ T cells were added in 1mL R10 + 50IU/mL of IL-2. All T cell infections were collected 48 hr post infection.

Flow cytometry {#s4-11}
--------------

Intracellular staining of cells using antibodies directed against HIV Gag p24, MR and FLAG-UNG2 was performed by permeabilizing paraformaldehyde-fixed cells with 0.1% Triton-X in PBS for 5 min, followed by incubation with antibody for 20 min at room temperature. For Gag and MR, PE-conjugated primary antibodies were used. For FLAG-UNG2, cells were stained with a PE-conjugated goat anti-mouse IgG1 secondary antibody for 20 min at room temperature. Surface staining for CD4, CD3 and CD14 was performed before fixation as described previously ([@bib15]). Flow cytometric data was acquired using a FACSCanto instrument with FACSDiva collection software (BD, Franklin Lakes, New Jersey) or a FACScan (Cytek, BD) with FlowJo software (TreeStar, Ashland, Oregon) and analyzed using FlowJo software. Live NL4-3 ∆GPE-GFP transduced cells were sorted using a FACSAria III (BD) or MoFlo Astrios (Beckman Coulter) and gating on GFP^+^ cells.

Quantitative RT-PCR {#s4-12}
-------------------

MDM sorted as described above in 'Flow cytometry' were collected into tubes containing RLT buffer (Qiagen, Hilden, Germany) and RNA was isolated using RNeasy Kit (Qiagen) with on-column DNase I digestion. RNA was reverse transcribed using qScript cDNA SuperMix (Cat \#95048, Quantabio, Beverly, Massachusetts). Quantitative PCR was performed using TaqMan Gene Expression MasterMix (ThermoFisher, cat\# 4369016) on an Applied Biosystems 7300 Real-Time PCR System using TaqMan Gene Expression primers with FAM-MGB probe. The primer/probe sets for *ACTB* (Hs99999903), *MRC1* (Hs00267207), *POL2A* (Hs02786624), and *GAPDH* (Hs00172187) were purchased from ThermoFisher. Reactions were quantified using ABI Sequence Detection software compared to serial dilutions of cDNA from mock-treated cells. Measured values for all genes were normalized to measured values of *GAPDH* or *ACTB* as indicated.

Immunoblot {#s4-13}
----------

MDM cultures were lysed in Blue Loading Buffer (cat\# 7722, Cell Signaling Technology), sonicated with a Misonix sonicator (Qsonica, LLC., Newtown, Connecticut), boiled for 5 min at 95°C and clarified by centrifugation at 8000 RPM (7,000 x *g*) for 3 min. Lysates were analyzed by SDS-PAGE immunoblot. The proteins MR, GAPDH and pr55 were visualized using AlexFluor-647 conjugated secondary antibodies on a Typhoon FLA 9500 scanner (GE, Boston, Massachusetts) and quantified using ImageQL (GE). The proteins gp160, gp120, gp41, Nef, Vpr, GFP, Env-GFP, STING, GBP5, and IFITM3 were visualized using HRP-conjugated secondary antibodies on film. Immunoblot films were scanned and the mean intensity of each band, minus the background, was calculated using the histogram function of Photoshop CC (Adobe, San Jose, California).

Virion quantitation {#s4-14}
-------------------

Supernatant containing viral particles was lysed in Triton X lysis buffer (0.05% Tween 20, 0.5% Triton X-100, 0.5% casein in PBS). Gag p24 antibody (clone 183-H12-5C, AIDS Reagent Program cat\# 1519 from Dr. Bruce Cheseboro and Dr. Hardy Chen) was bound to Nunc MaxiSorp plates (ThermoFisher cat\# 12-565-135) at 4°C overnight. Lysed samples were captured for 2 hr and then incubated with biotinylated antibody to Gag p24 (clone 31-90-25, ATCC cat\# HB-9725) for 1 hr. Clone 31-90-25 was biotinylated with the EZ-Link Micro Sulfo-NHS-Biotinylation Kit (ThermoFisher cat\# PI-21925). Clones 31-90-25 and 182-H12-5C were purified using Protein G columns (GE Healthcare, cat\# 45-000-054) following the manufacturer's instructions. Samples were detected using streptavidin-HRP (Fitzgerald, Acton, Massachusetts) and 3,3′,5,5′-tetramethylbenzidine substrate (Sigma cat\# T8665-IL). CAp24 concentrations were measured by comparison to recombinant CAp24 standards (cat\# 00177 V, ViroGen, Watertown, Massachusetts).

Antibodies {#s4-15}
----------

Antibodies to CAp24 (clone KC57-PE cat\# 6604667 and KC57-FITC cat\# 6604665, Beckman Coulter, Brea, California), CD3 (clone OKT3-Pacific Blue, cat\# 317313, BioLegend, San Diego, California), CD14 (clone HCD14-APC, cat\# 325608, BioLegend), CD4 (clone OKT4, cat\#17-0048-42, Invitrogen, ThermoScientific), FLAG (clone M2, cat\#F3165, Sigma), and MR (clone 19.2-PE, cat\# 555954, BD) were used for flow cytometry. Antibodies to the following proteins were used for immunoblot analysis: MR (cat\# ab64693, Abcam, Cambridge, Massachusetts), GAPDH (clone 3C2, cat\# H00002597-M01, Abnova, Taipei, Taiwan), Gag pr55 (HIV-Ig AIDS Reagent Program cat\# 3957), Env gp160/120 (AIDS Reagent Program cat\# 288 from Dr. Michael Phelan), 89.6 and YU-2 Env gp41 (clone z13e1, AIDS Reagent Program cat\# 11557 from Dr. Michael Zwick), NL4-3 Env gp41 (clone CHESSIE-8, AIDS Reagent Program cat\# 526 from Dr. George Lewis), Vpr (AIDS Reagent Program cat\# 3951 from Dr. Jeffrey Kopp), GFP (cat\# ab13970, Abcam), Nef (AIDS Reagent Program cat\# 2949 from Dr. Ronald Swanstrom), FLAG (clone M2, cat\# F3165, Sigma), STING (D2P2F, cat\# 13647, Cell Signaling Technology), GBP5 (sc-160353, which was a generous gift from Dr. Frank Kirchhoff), and IFITM3 (cat\# 11714--1-AP, Proteintech, Rosemont, IL). Neutralizing antibody 2G12 (AIDS Reagent Program cat\# 1476 from Dr. Hermann Katinger) was used at a 1 μg/mL at the time of infection. Antibody clone CHESSIE-8 was purified using Protein G columns (GE Healthcare, cat\# 45-000-054) following the manufacturer's instructions.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious Diseases R21AI132379 to Jay Lubow, Maria C Virgilio, Brian G Peterson, Kathleen L Collins.

-   http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious Diseases R56AI120954 to David R Collins, Michael Mashiba, Kathleen L Collins.

-   http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious Diseases R56AI130004 to Jay Lubow, Maria C Virgilio, Brian G Peterson, Kathleen L Collins.

-   http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious Diseases RO1AI51192 to David R Collins, Michael Mashiba, Kathleen L Collins.

-   http://dx.doi.org/10.13039/100000057National Institute of General Medical Sciences T32GM008353-28 to Jay Lubow.

This research was supported by the NIH (5T32GM008353-27 to JL, F31AI125090-01 to JL, R01AI046998 to KLC, R56AI130004 to KLC, R21AI32379 to KLC, T32GM007863 to MM, T32AI007413 to MM and T32AI007528 to DRC). We are grateful to the University of Michigan Vector Core and the NIH AIDS Reagent Program for reagents and to the University of Michigan Flow Cytometry Core for assistance with experiments. We thank Dr. Estelle Chiari for providing pMSCV 3xFLAG UNG2 IRES-GFP

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Resources, Formal analysis, Investigation, Methodology.

Formal analysis, Investigation, Methodology.

Investigation, Visualization.

Conceptualization, Resources, Formal analysis, Funding acquisition, Investigation.

Conceptualization, Resources, Formal analysis, Funding acquisition.

Formal analysis, Investigation.

Resources, Investigation.

Investigation.

Investigation.

Resources, Investigation.

Investigation.

Conceptualization, Supervision, Funding acquisition.

Additional files {#s6}
================

###### Key resources table.

Data availability {#s7}
=================

The study did not generate large data sets. All necessary data are included in figures.

10.7554/eLife.51035.sa1

Decision letter

Overbaugh

Julie

Reviewing Editor

Fred Hutchinson Cancer Research Center

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This paper ties together observations that HIV replicates to low levels in monocytes and that the accessory gene vpr plays a role in this lower replication with recent findings that vpr counteracts a macrophage specific factor that targets Env. As a result, expression of Vpr increases steady-state levels of Env in infected macrophages. The present study focused on the mannose receptor, which was previously shown to bind HIV Env and is highly expressed in macrophages. Here they show that vpr downregulates mannose receptor expression, thereby avoiding an innate response driven by this receptor and increasing Env expression and HIV replication. Given that macrophages are an important cell type for HIV replication in vivo, this study advances our understanding of how virus replication is regulated in this key host cell of HIV.

**Decision letter after peer review:**

Thank you for sending your article entitled \"Mannose receptor is a restriction factor of HIV in macrophages and is counteracted by the accessory protein Vpr\" for peer review at *eLife*. Your article is being evaluated by 3 peer reviewers, and the evaluation is being overseen by a Reviewing Editor and Satyajit Rath as the Senior Editor.

This work from Lubow et all seeks to build on previous publications from the lab and identify an antiviral restriction factor of HIV in macrophage cells that is overcome by the accessory gene Vpr. They identified Manose Receptor (MR) as a target of both Vpr and Nef. They focus on Vpr because this role of Nef has been described and Vpr appears to have a similar level of effect as Nef. The authors make a solid case that MR affects Env expression in the absence of Vpr and Nef and that MR is responsible for limiting virus spread from MDM to T cells in the absence of Vpr. The overall finding is interesting although the results are disjointed at times -- changes of virus types that make it harder to tell what is driving differences and some key controls are needed. But overall, with proper controls, the study identifies an interest virus/host cell interaction that may help explain aspects HIV replication in macrophages

The reviewers were generally positive but had a fairly long list of major concerns that would need to be addressed. Some common and important themes of the reviewers include: Some controls are needed, including for the degradation assay such as including a Vpr mutant control and a substrate control. Controls, transparency of the data were common themes of the reviews that need to be addressed. A more balanced view of the role of Nef and Vpr in this activity given Nef effect is at least as potent as Vpr so if it is modest, then Vpr is also modest. Figure 7 should be removed as it is peripheral and based on limited data. Ideally, including studies with more relevant viruses would strengthen the paper and at the very least, describing this limitation in the studies and the fact that different viruses were used for different experiments, which could confound interpretation in the Discussion. Likewise, statements about the work explaining vpr conservation seem unfounded overall, and even more so given the viruses tested, so these reviewers\' issues needed to be addressed. Statistical tests should be applied to support conclusions where appropriate. Also, many errors were evident in the figures and legends and these should be looked at carefully.

Reviewer \#1:

This paper pulls together observations that HIV replicates to low levels in monocytes and that vpr plays a role in this lower replication with recent findings that vpr counteracts a macrophage specific factor that targets Env. The present study focused on the mannose receptor, which was previously shown to bind HIV Env and is highly expressed in macrophages. Here they show that vpr downregulates MR expression, thereby avoiding an innate response driven by this receptor and increasing HIV replication. The overall finding is interesting although the results are disjointed at times -- changes of virus types that make it harder to tell what is driving differences, a study of T cell infection that seems peripheral, as discussed below.

1\) The author suggests Figure 5E shows differences in infectivity of select mutants. That is not evident from the figure as differences are subtle and less than two fold and there are no significant differences indicated. If the differences are not statistically significant the authors should tone down these claims that MR is important for entry/replication throughout. This would include removing --the end of the fifth paragraph of the Discussion.

2\) In the shMR cells, it would be nice to see a traditional virus replication study to get a better sense of the KO effects, rather than a single time point since this is an important part of the paper.

3\) I don\'t understand how Figure 7 fits in this study. It does not examine the MR or vpr and it now shifts to the study of T/F viruses, which are not used elsewhere (which is too bad -- see below). It seems like an ad on. Related to that, the second paragraph of the Discussion does not appear to be accurate as they did not demonstrate effects of vpr and MR on virus spread to T cells. If they want to do the experiments to show this, that would be a good addition and allow for some nice conclusions and strengthen the paper. Otherwise the T cell spread aspect and Figure 7 should be removed. And the last paragraph of the Discussion.

4\) 89.6 is such a weird HIV variant, it would be nice to see this using a virus that is actually representative of circulating macrophage-tropic viruses. Likewise, for NL4.3 -- very culture adapted. This may be especially relevant given YU2 behaves differently from these viruses, which may or may not be due to the mannose patch differences since there are many other glycans on env. Making vpr and nef mutants and even the mannose patch mutants in REJO or a similar stain and showing and testing them in wt versus shMR cells would help tie this story together. The changing of strains for different experiments makes interpretations more difficult and a clean set of key experiments with one macrophage tropic virus that is not highly adapted in culture would make this a stronger paper.

Reviewer \#2:

This work from Lubow et all seeks to build on previous publications from the lab and identify an antiviral restriction factor of HIV in macrophage cells that is overcome by the accessory gene Vpr. They identified Manose Receptor (MR) as a target of both Vpr and Nef. While the data is overall convincing to support repression of MR by both Vpr and Nef, the authors chose to focus on Vpr and largely ignore Nef, even though it has a greater effect on MR levels. Moreover, the mechanistic details of how Vpr alters MR are very underdeveloped, as are their investigations into how MR inhibits Env and virion production. Finally, the overall flow of the paper was disjointed, and felt like two partially complete studies fused into one. In summary, while the data showing that both Vpr and Nef downregulate MR expression are convincing, the mechanistic insights into how and why this is achieved by two distinct lentiviral accessory proteins is lacking. This would help to make the paper more well-rounded and complete.

1\) It is difficult to assess whether the effect of Vpr on MR/MRC1 is direct, or simply due to the many cellular effects of Vpr expression. Moreover, the authors do not sufficiently investigate how Vpr inhibits MR expression. For example:

a\) In Figure 1, the authors screened \"candidate Env binding proteins\" but only show data for MR. It would help to show additional candidates to highlight the specificity of MR degradation.

b\) In Figure 2, roughly 20-45% of GFP+ (HIV infected cells) have decreased MR despite being targeted by two viral proteins -- why is this, and what does it suggest about MR downregulation?

c\) In Figure 2 and Figure 2---figure supplement 1 the authors use an overexpression assay in 293T cells and qRT-PCR of MRC1 to suggest that MR is not degraded by Vpr, however no controls for their degradation assay are shown (such as UNG), no western blots to show expression of MR or Vpr are shown, and only MRC1 mRNA levels are looked at, which is concerning given the large effects of Vpr on cellular transcription.

2\) Figures 2 and 3 clearly show that Nef functions slightly better than Vpr at inhibiting MR expression, yet the authors state that the effect of Nef is \"modest\" and \"the effect of Nef alone was relatively small\". Subsequently, Nef is largely ignored throughout the rest of the manuscript. It would be beneficial for the authors to clearly demonstrate why they think Vpr, and not Nef, is the primary driver of the observed phenotypes.

3\) There are experimental details and controls missing throughout the manuscript. While some of these are minor on their own, given that much of the data is normalized, this lack of transparency and controls makes the data difficult to truly assess overall.

Some examples: a) \"Relative p24 release\" is shown for many of the later figures, when p24 or GFP is used in early figures. Why is p24/GFP not shown throughout?

b\) Many of the figures rely on quantification of western blots; however, HRP was used for many panels and compared to AlexaFluor antibodies. HRP is not a quantitative reagent, and should not be used as such.

c\) Loading controls are missing from some western blots (ex 3A, 3E, 5C, 5I, etc).

d\) MDMs are differentiated using both M-CSF and GM-CSF; this is concerning as those cytokines lead to different macrophage phenotypes (such as highlighted here https://www.jimmunol.org/content/188/11/5752). Figure 1 shows MDMs more like GM-CSF MDMs, but Figure 6 indicates MDMs that sit somewhere in the middle. In addition, the MDMs seem to be CD3 positive (Supplementary Figure 2), which they should not be.

e\) It is unclear why the authors use 10-day single round infections, which is unconventional. Moreover, the authors do not explain their methodology. For example, are the entry inhibitors replenished in the 8 days between their addition and experimental completion? It is highly doubtful the inhibitors can last for 8 days, so if they are not changed then the infection will not likely be single round.

f\) Different y-axis scales are used even when discussing the same assay like p24 ELISA results (i.e. 4A vs. 4E.). Sometimes log 10, log 2, or linear...

g\) Figure 7 is n=1 donor. Given the slight differences observed, given how variable different donor primary cells can be, and given the conclusions generated from this figure, this must be repeated with multiple donors.

4\) The authors repeatedly use 293T cells as a control to show the observed effects are macrophage specific. However, 293Ts are highly transformed, rapidly cycling, lab adapted cells that do not make a good biological control cell when comparing to primary MDMs. THP-1 +/- PMA (to show cycling vs. non-cycling monocytic cell lines) or even primary T cells would be a better control to allow for biologically relevant conclusions.

5\) I am wrestling with the biological significance of MR in HIV replication, spread, and evolution, especially given the statement that this work \"provide(s) an explanation for the evolutionary conservation of Vpr\"... The authors highlight the lack of manose patch naturally found in the macrophage-tropic YU-2 HIV isolate. If this is indeed a central target of MR and YU-2 has evolved without the manose patch in order to circumvent this restriction, then one would assume other macrophage-tropic viruses would also be selected to have lost similar glycan structures to increase viral fitness and avoid MR restriction. Have the authors looked for this? That said, if macrophage-tropic viruses are more fit by losing the manose patch to avoid MR, then why would two accessory genes (Vpr and Nef) be needed to deplete MR through two potentially independent mechanisms? Have the authors looked at Vpr and Nef from these macrophage-tropic viruses to see if they still inhibit MR expression? This might help explain the potential discrepancy.

Reviewer \#3:

The authors previously reported that HIV-1 Vpr counteracts an unidentified macrophage-specific factor that targets Env and Env-containing virions for lysosomal degradation. Thus, expression of Vpr increases steady-state levels of Env in infected MDM. In the current study, the authors investigate the possible involvement of mannose receptor (MR). MR expression was previously shown to be downmodulated in HIV-infected MDM and HIV Tat and Nef were implicated in this phenomenon. Tat was proposed to cause transcriptional repression of the MR promoter whereas Nef was shown to cause cell-surface downmodulation of MR without effect on MR steady-state levels. Here the authors confirm the reported effect of Nef on MR surface expression. The authors did not specifically look at a possible inhibitory effect of Tat on MR transcription and, as far as I am concerned, their data do not categorically rule out a contribution of Tat. However, the data presented here are indeed more consistent with the authors\' conclusion that it is Vpr that induces transcriptional repression of MR. Somewhat surprisingly, Vpr appeared to be sufficient to cause efficient inhibition of MR expression in MDM in a spreading infection experiment (Figure 1C), but had only a partial effect on MR surface expression in a single cycle infection study (Figure 2D) and required the additional presence of Nef for efficient downmodulation of MR. I am not quite sure what to make of that. Nevertheless, the authors go on to demonstrate that the previously reported effect of Vpr on Env expression involves MR and silencing of MR reduced the requirement for Vpr for efficient Env expression. Overall, this is an interesting study that is timely and provides novel insights into the interplay of Env, Vpr, Nef, and mannose receptor. The authors make a convincing case that MR affects Env expression in the absence of Vpr and Nef and that MR is responsible for limiting virus spread from MDM to T cells in the absence of Vpr. The manuscript is well written and the experiments are for the most part well-designed and executed. I do have a few issues as detailed below that require the authors attention.

1\) Figure 1: Multiple studies have documented that replication of Vpr-deficient HIV-1 in macrophages is severely restricted when compared to wild type (wt) virus (e.g. Connor et al., 1995). I find it therefore astonishing that in panels C and E of Figure 1, there is only a minor difference in the pr55 levels of cells infected with wt and vpr-null virus. At 10 days post infection I would have expected a much larger difference in the Gag levels. In the figure legend and in the text the authors talk about \"matched infection frequencies\" but they don\'t explain how this was accomplished.

2\) Also, I find it interesting that the authors go out of their way to document differences in Env levels by showing not only gp160 (the Env equivalent of pr55) but, in addition gp120 and gp41. Yet, they don\'t show p24 (CA). Showing the entire Gag blots (or at least inclusion of CA) might be informative since p24 antibodies typically have a higher affinity to p24 than to the pr55 precursor.

3\) How does the strong reduction of MR in Figure 1C at the protein level by just Vpr fit with the data from Figure 2D where both Nef and Vpr were required for efficient cell-surface down-modulation of MR in a single round infection?

4\) Figure 2D and G: How do the authors explain that only a subset of GFP+ cells downregulate MR? They skirt this issue both in the text and in the Discussion. In their Discussion, the authors make a statement concerning the importance of Env expression for Vpr-sensitive restriction in MDM. Since the construct used here is Env-defective, cells should be stained for intracellular p24 to see whether the Gag expression pattern matches that of GFP or MR (obviously it can\'t be both).

5\) Figure 1---figure supplement 1: The authors should include a Q65R mutant of Vpr in the analysis to strengthen the argument that Vpr-mediated downmodulation of MR is DCAF1-independent.

6\) Figure 3C/D: Donor 2: The% Gag-positive cells on day 10 is almost identical for wt and vpr-null samples. In contrast, virus output in panel D on day 10 is significantly lower for the vpr-null virus. Does that mean virus spreads mostly in a cell-to-cell manner in MDM? Does it correlate with low MR levels?

7\) Nef does a lot of things but I am not aware of any literature reporting an effect of Nef on Env stability. What did I miss?

8\) Figure 3E: Deletion of Nef alone reduces Env expression almost as much as deleting both Nef and Vpr. How can this be explained? Is it correlated with effect on MR expression? A MR western blot should be included here. But even if the effect of Nef deletion involves MR how can this work if Nef only affects MR surface expression and not total cellular pool of MR?

9\) Figure 5I: The authors conclude from this experiment that MR restricts Env expression via direct interaction with high-mannose residues on Env. Where in the cell is this happening? What happens if cells are treated with Brefeldin A, which traps Env and MR in the ER? Will it exacerbate/alleviate the effect of MR on Env?

10). "MR is the restriction factor".... -- I would suggest softening this statement to \"MR is a restriction factor\".

11\) Discussion: \"In the primary macrophage system, Vpr-sensitive virion restriction depends entirely on an intact env open reading frame (Mashiba et al., 2014)\". What are the implications of this statement for the data shown in Figure 2 where Env was replaced by GFP?

12\) Discussion:\" The magnitude of the effect and the fraction of cells affected increased when both proteins were expressed\". What does the \"fraction of cells\" statement mean? Are the authors suggesting that this is an \"either-or\" phenomenon where Nef downmodulates MR in one fraction of the cells and Vpr does the same but in another fraction and only together do we see downmodulation in the two fractions combined? That would be fantastic from a mechanistical point of view and would explain the results from but is very unrealistic, I am afraid.

13\) The fourth paragraph of the Discussion is somewhat trivial and can be deleted without loss to content and clarity of the paper. Instead, the authors should simply include the Q65R control as suggested for Figure 1---figure supplement 1 above. That\'s a quick and easy experiment to do.

10.7554/eLife.51035.sa2

Author response

> Reviewer \#1:
>
> This paper pulls together observations that HIV replicates to low levels in monocytes and that vpr plays a role in this lower replication with recent findings that vpr counteracts a macrophage specific factor that targets Env. The present study focused on the mannose receptor, which was previously shown to bind HIV Env and is highly expressed in macrophages. Here they show that vpr downregulates MR expression, thereby avoiding an innate response driven by this receptor and increasing HIV replication. The overall finding is interesting although the results are disjointed at times -- changes of virus types that make it harder to tell what is driving differences, a study of T cell infection that seems peripheral, as discussed below.
>
> 1\) The author suggests Figure 5E shows differences in infectivity of select mutants. That is not evident from the figure as differences are subtle and less than two fold and there are no significant differences indicated. If the differences are not statistically significant the authors should tone down these claims that MR is important for entry/replication throughout. This would include removing --the end of the fifth paragraph of the Discussion.

In revised Figure 6E (was 5E in the first draft), data from MDM from 6 independent donors are compiled. They show that infection by the mannose-depleted Env mutant is consistently reduced about 40% compared to the wild-type Env and that these differences are statistically significant in MDM but not in MOLT4-R5 T cells, which lack MR. Additionally, our claim is supported by Figure 5F showing that mannan inhibits infection of MR-expressing macrophages, but not infection of the MOLT4-R5 T cell line. Moreover, we show that VSV-G pseudotyping HIV rescues this inhibition, which makes sense as VSV-G is not mannosylated.

> 2\) In the shMR cells, it would be nice to see a traditional virus replication study to get a better sense of the KO effects, rather than a single time point since this is an important part of the paper.

As shown in Figure 6 and discussed above, MR has both positive and negative effects on infection; our data indicate it is a positive factor for entry and a negative factor for egress, which is somewhat analogous to CD4 and chemokine receptors in the sense that they are needed for entry but can interfere with viral egress and spread. Thus, the effects of silencing on overall infection are complicated to interpret. Some donors had increased infection resulting from MR silencing whereas others had a small decrease at the ten-day time point. Variations in baseline MR expression likely also contributed to a degree of heterogeneity in our results. We added a paragraph in the Discussion to address this interesting point.

> 3\) I don\'t understand how Figure 7 fits in this study. It does not examine the MR or vpr and it now shifts to the study of T/F viruses, which are not used elsewhere (which is too bad -- see below). It seems like an ad on. Related to that, the second paragraph of the Discussion does not appear to be accurate as they did not demonstrate effects of vpr and MR on virus spread to T cells. If they want to do the experiments to show this, that would be a good addition and allow for some nice conclusions and strengthen the paper. Otherwise the T cell spread aspect and Figure 7 should be removed. And the last paragraph of the Discussion.

In response to the reviewer's concern, we added Vpr data and moved these results as they largely confirmed findings from a prior study (Collins et al., 2015). These data are now included in Figure 7---figure supplement 1. In addition, we added data from additional donors to revised Figure 7, which strengthened our conclusion that Vpr modulated spread from macrophages to T lymphocytes in an MR-dependent manner.

> 4\) 89.6 is such a weird HIV variant, it would be nice to see this using a virus that is actually representative of circulating macrophage-tropic viruses. Likewise, for NL4.3 -- very culture adapted. This may be especially relevant given YU2 behaves differently from these viruses, which may or may not be due to the mannose patch differences since there are many other glycans on env. Making vpr and nef mutants and even the mannose patch mutants in REJO or a similar stain and showing and testing them in wt versus shMR cells would help tie this story together. The changing of strains for different experiments makes interpretations more difficult and a clean set of key experiments with one macrophage tropic virus that is not highly adapted in culture would make this a stronger paper.

In previously published work, we demonstrated that 89.6, NL4-3 and AD8 behave similarly with respect to these assays. In other words, Vpr from each of these molecular clones similarly stabilizes Env, promotes virion release and stimulates spread from T cells to macrophages (Mashiba et al., 2014) and (Collins et al., 2015). In the revised manuscript, we provide new data on the transmitter/founder virus REJO that demonstrate it behaves similarly.

Thus far, YU2 is the only variant we have tested that has a diminished requirement for Vpr in macrophages and this property may be unique to this molecular clone. We show here that genetically altering the mannose patch on 89.6 so that it mirrored changes in the YU-2 mannose patch altered the behavior of 89.6 to resemble that of YU-2 with respect to Vpr phenotypes. This is strong evidence supporting our model that Vpr alleviates deleterious interactions caused by the Env mannose patch. Interestingly, YU-2 was cloned from the central nervous system (CNS) and 89.6 was directly cloned from peripheral blood. Because the blood-brain barrier limits exposure to antibodies, CNS isolates may have a diminished requirement for high mannose residues, which protect from antibody responses. We have revised the Discussion to include these points. In future experiments we will commit a focused effort towards examining a panel of CNS-derived HIV isolates to further test this interesting hypothesis.

> Reviewer \#2:
>
> This work from Lubow et all seeks to build on previous publications from the lab and identify an antiviral restriction factor of HIV in macrophage cells that is overcome by the accessory gene Vpr. They identified Manose Receptor (MR) as a target of both Vpr and Nef. While the data is overall convincing to support repression of MR by both Vpr and Nef, the authors chose to focus on Vpr and largely ignore Nef, even though it has a greater effect on MR levels. Moreover, the mechanistic details of how Vpr alters MR are very underdeveloped, as are their investigations into how MR inhibits Env and virion production. Finally, the overall flow of the paper was disjointed, and felt like two partially complete studies fused into one. In summary, while the data showing that both Vpr and Nef downregulate MR expression are convincing, the mechanistic insights into how and why this is achieved by two distinct lentiviral accessory proteins is lacking. This would help to make the paper more well-rounded and complete.
>
> 1\) It is difficult to assess whether the effect of Vpr on MR/MRC1 is direct, or simply due to the many cellular effects of Vpr expression. Moreover, the authors do not sufficiently investigate how Vpr inhibits MR expression. For example:
>
> a\) In Figure 1, the authors screened \"candidate Env binding proteins\" but only show data for MR. It would help to show additional candidates to highlight the specificity of MR degradation.

In revised Figure 1---figure supplement 1, we provide these data, which provide evidence for a selective effect of Vpr on MR. We also provide additional RNA data for cellular genes other than MR that supports this conclusion (Figures 3 and Figure 3---figure supplement 1).

> b\) In Figure 2, roughly 20-45% of GFP+ (HIV infected cells) have decreased MR despite being targeted by two viral proteins -- why is this, and what does it suggest about MR downregulation?

The reviewer is correct about these results collected 5 days post transduction. Western blot analysis of whole cell lysates from our ten-day culture (Figure 1D) suggests more uniform effects at longer time points and suggest MR downregulation is time-dependent in macrophages, which tolerate HIV infection for weeks. This time dependency is potentially explainable in part by very long half-life of MR (33 hours) (Lennartz, Cole and Stahl, 1989). Additionally, as we mention in the Discussion, MR is present at very high levels on macrophages (100,000 per cell) and it is likely that Vpr and Nef both require high level expression to achieve maximal effect.

> c\) In Figure 2 and Figure 2---figure supplement 1 the authors use an overexpression assay in 293T cells and qRT-PCR of MRC1 to suggest that MR is not degraded by Vpr, however no controls for their degradation assay are shown (such as UNG), no western blots to show expression of MR or Vpr are shown, and only MRC1 mRNA levels are looked at, which is concerning given the large effects of Vpr on cellular transcription.

An updated Figure 2---figure supplement 1 contains flow cytometry data and western blots demonstrating that under the conditions of our expression assay in 293T cells, Vpr degrades UNG2 but has no effect on MR.

As mentioned above, the qPCR data examining MR RNA expression in primary human macrophages have been strengthened significantly. We extended our analysis to additional cellular genes (GAPDH and POL2A) and increased the number of donors tested. We consistently observed that Vpr expression reduced MR mRNA levels but did not alter those of GAPDH or POL2A.

> 2\) Figures 2 and 3 clearly show that Nef functions slightly better than Vpr at inhibiting MR expression, yet the authors state that the effect of Nef is \"modest\" and \"the effect of Nef alone was relatively small\". Subsequently, Nef is largely ignored throughout the rest of the manuscript. It would be beneficial for the authors to clearly demonstrate why they think Vpr, and not Nef, is the primary driver of the observed phenotypes.

Our conclusions are based on the compiled data, which summarizes results from multiple donors. Across 7 donors as shown in Figure 2E, the difference between Vpr and Nef-null viral mutants was not statistically significant. Our data indicate that both Vpr and Nef are required for MR downmodulation, but neither is sufficient. Compared to the Vpr-Nef-null double mutant, the Vpr-null mutant (which has Nef) had a small effect, as did the Nef-null mutant (which has Vpr). The results have been re-written to make this point clearer and the representative image in Figure 2D is more reflective of the compiled data.

While both Vpr and Nef play a role in MR downmodulation, the discovery of this role for Vpr has not been previously reported whereas Nef's effects on MR are not novel. Thus, we focused on Vpr.

> 3\) There are experimental details and controls missing throughout the manuscript. While some of these are minor on their own, given that much of the data is normalized, this lack of transparency and controls makes the data difficult to truly assess overall.
>
> Some examples: a) \"Relative p24 release\" is shown for many of the later figures, when p24 or GFP is used in early figures. Why is p24/GFP not shown throughout?

GFP is used in our single round infections shown in Figure 2 to identify the subset of cells that are infected by flow cytometry. Our full length, wild type viruses do not include any marker genes, so GFP cannot be used in any subsequent figures. In these cases, we use intracellular Gag in place of GFP to identify infected cells and this allows us to determine a rough assessment of "burst size" (p24 produced per infected cell frequency). In most figures the p24 production and infection rates varied significantly across donors, but p24 release per cell was always lower in the mutants than the wild type. To show this result clearly, all values for the mutants were normalized to Wt before being compiled. To improve transparency, the revised manuscript includes raw p24 ELISA and Gag+ frequency data. The corresponding data for Figures 5 and 6 are provided in Figure 5---figure supplement 1 and Figure 6---figure supplement 1 respectively. For Figure 4, these data were provided as part of the main figure.

> b\) Many of the figures rely on quantification of western blots; however, HRP was used for many panels and compared to AlexaFluor antibodies. HRP is not a quantitative reagent, and should not be used as such.

We agree that HRP and ECL have a lower dynamic range than fluorescent antibodies coupled with imaging systems. However, AlexaFluor secondary antibodies did not produce reliable results for the Env proteins. To overcome this limitation, we made great effort to demonstrate that we were operating under conditions of relative linearity by providing serial dilutions of wild-type infected lysates for blots stained with ECL. This semi-quantitative analysis provided reproducible fold-differences between wild type and mutant Env expression levels across multiple donors.

> c\) Loading controls are missing from some western blots (ex 3A, 3E, 5C, 5I, etc).

All western blots for host proteins have GAPDH as a loading control. For western blots of viral proteins, we feel that pr55 is the most useful control as it is a proxy for viral protein expression. For blots that analyze both host and viral proteins, GAPDH and pr55 are both shown.

> d\) MDMs are differentiated using both M-CSF and GM-CSF; this is concerning as those cytokines lead to different macrophage phenotypes (such as highlighted here https://www.jimmunol.org/content/188/11/5752). Figure 1 shows MDMs more like GM-CSF MDMs, but Figure 6 indicates MDMs that sit somewhere in the middle.

While differences were seen between macrophages treated with each cytokine individually in the published paper provided by the reviewer, in our study all donor macrophages were treated with both cytokines. Similar to other investigators, we have noted significant donor variability but we do not have any reason to believe this is due to the cytokines used to prepare them. The dual cytokine protocol we used for macrophage differentiation and infection was communicated to us by the Siliciano lab as an experimental approach that facilitates macrophage infection by HIV. This protocol is fairly standard in the field, being utilized and published by other HIV investigators e.g. (Lahouassa, Daddacha et al. 2012, Mashiba et al., 2014, Collins et al., 2015, Chougui, Munir-Matloob et al., 2018, Clayton, Collins et al. 2018).

> In addition, the MDMs seem to be CD3 positive (Supplementary Figure 2), which they should not be.

Macrophages have more autofluorescence than T cells because of their larger size. We have added flow cytometry plots (Figure 7---figure supplement 1C) to demonstrate that the PacBlue signal observed in macrophages is roughly equal in unstained, isotype-control stained, and anti-CD3-stained MDM, indicating there is no significant CD3 expression on MDMs as expected. By contrast PBMCs show a clear CD3-specific signal compared to isotype control, indicating CD3 expression.

> e\) It is unclear why the authors use 10-day single round infections, which is unconventional. Moreover, the authors do not explain their methodology. For example, are the entry inhibitors replenished in the 8 days between their addition and experimental completion? It is highly doubtful the inhibitors can last for 8 days, so if they are not changed then the infection will not likely be single round.

We thank the reviewers for pointing out these methodological points that are potentially confusing to readers. We have clarified in the revised manuscript that this methodology was chosen to make the single round infection experiments as similar as possible to the 10 day spreading infections, which we believed showed stronger phenotypes due to the long half-life of mannose receptor. Also, the legends and Materials and Methods have been amended to clarify that entry inhibitors were replenished in culture medium every 3 days.

> f\) Different y-axis scales are used even when discussing the same assay like p24 ELISA results (i.e. 4A vs. 4E.). Sometimes log 10, log 2, or linear...

All ELISA results from MDM are now displayed on a log scale.

> g\) Figure 7 is n=1 donor. Given the slight differences observed, given how variable different donor primary cells can be, and given the conclusions generated from this figure, this must be repeated with multiple donors.

In response to this concern, we performed additional experiments to increase the number of donors included in this analysis. In the revised manuscript, these data were moved to Figure 7---figure supplement 1E because they largely replicate our previously published results with a different HIV strain.

> 4\) The authors repeatedly use 293T cells as a control to show the observed effects are macrophage specific. However, 293Ts are highly transformed, rapidly cycling, lab adapted cells that do not make a good biological control cell when comparing to primary MDMs. THP-1 +/- PMA (to show cycling vs. non-cycling monocytic cell lines) or even primary T cells would be a better control to allow for biologically relevant conclusions.

The 293T cells were useful due to their high transfectability to demonstrate that the mutations we made in various genes did not disrupt expression of other HIV proteins unintentionally. We will clarify that as the primary conclusion of these experiments in the revised manuscript.

We have tested THP-1 cells; however, they were difficult to infect with non-pseudotyped wild type viruses and do not express MR or demonstrate Vpr dependent phenotypes. We do include infections of the T cell line MOLT4-R5 in Figure 5 and we use primary T cells as controls in Figure 7. In two prior publications we demonstrated that activated primary T cells do not display Vpr infection and virion production phenotypes when cultured alone under the conditions of our assay (Mashiba et al., 2014, Collins et al., 2015). We considered performing western blots using primary T cells to examine the effect of Vpr-Nef double mutants on Env. However, it's known that Nef downmodulates CD4, which is expressed at high levels in T cells and this activity of Nef likely stabilizes Env expression in T cells. Thus, this experiment is of limited utility in the context of the question being asked here. A paragraph in the Discussion (3^rd^ paragraph) has been amended to discuss how effects of Nef on MR likely contribute to but do not fully explain the downmodulation of Env we observe in the Nef and Nef-Vpr double mutants. Beyond that, we respectfully request clarification about what question the reviewer wants addressed that affects our conclusion that Vpr overcomes a restriction of HIV infection in macrophages that is mediated by MR.

> 5\) I am wrestling with the biological significance of MR in HIV replication, spread, and evolution, especially given the statement that this work \"provide(s) an explanation for the evolutionary conservation of Vpr\"... The authors highlight the lack of manose patch naturally found in the macrophage-tropic YU-2 HIV isolate. If this is indeed a central target of MR and YU-2 has evolved without the manose patch in order to circumvent this restriction, then one would assume other macrophage-tropic viruses would also be selected to have lost similar glycan structures to increase viral fitness and avoid MR restriction. Have the authors looked for this? That said, if macrophage-tropic viruses are more fit by losing the manose patch to avoid MR, then why would two accessory genes (Vpr and Nef) be needed to deplete MR through two potentially independent mechanisms? Have the authors looked at Vpr and Nef from these macrophage-tropic viruses to see if they still inhibit MR expression? This might help explain the potential discrepancy.

Thus far, all the viruses we have tested in this and previous publications have yielded a consistent pattern with respect to Env restriction in macrophages and Vpr alleviation of that restriction with the exception of YU-2.

As we have written in the revised manuscript, we hypothesize that YU-2 has distinct characteristics with respect to the mannose patch because of its localization within the CNS, which changes the balance of selective factors experienced by the virus. Macrophage-tropic HIVs are selected within the CNS because macrophages are abundant and T cells are rare within this compartment (Joseph, Arrildt et al. 2014). Highly macrophage tropic HIVs evolve the capacity to bind low levels of CD4, and YU2 is one example of this phenomenon (Thomas, Dunfee et al. 2007).

The mannose patch is beneficial because it is protective against antibody recognition. Thus, antibodies serve as a selective force for maintenance of the mannose patch. Because antibodies are expressed at very low levels in the CNS they likely impose substantially less selective pressure on HIVs present in the CNS, such as YU-2.

In addition, interactions between MR and Env are beneficial to the virus because these interactions facilitate initial infection by free virus. (Figures 6E and 6F), Because YU-2 utilizes low levels of CD4 so efficiently, YU-2 likely benefits less from interactions between MR and Env.

Through Nef and Vpr, the virus has evolved mechanisms to derive maximal benefit from the positive effects of the mannose patch, while avoiding detrimental ones. We clarified these points in the revised manuscript.

> Reviewer \#3:
>
> The authors previously reported that HIV-1 Vpr counteracts an unidentified macrophage-specific factor that targets Env and Env-containing virions for lysosomal degradation. Thus, expression of Vpr increases steady-state levels of Env in infected MDM. In the current study, the authors investigate the possible involvement of mannose receptor (MR). MR expression was previously shown to be downmodulated in HIV-infected MDM and HIV Tat and Nef were implicated in this phenomenon. Tat was proposed to cause transcriptional repression of the MR promoter whereas Nef was shown to cause cell-surface downmodulation of MR without effect on MR steady-state levels. Here the authors confirm the reported effect of Nef on MR surface expression. The authors did not specifically look at a possible inhibitory effect of Tat on MR transcription and, as far as I am concerned, their data do not categorically rule out a contribution of Tat. However, the data presented here are indeed more consistent with the authors\' conclusion that it is Vpr that induces transcriptional repression of MR. Somewhat surprisingly, Vpr appeared to be sufficient to cause efficient inhibition of MR expression in MDM in a spreading infection experiment (Figure 1C), but had only a partial effect on MR surface expression in a single cycle infection study (Figure 2D) and required the additional presence of Nef for efficient downmodulation of MR. I am not quite sure what to make of that. Nevertheless, the authors go on to demonstrate that the previously reported effect of Vpr on Env expression involves MR and silencing of MR reduced the requirement for Vpr for efficient Env expression. Overall, this is an interesting study that is timely and provides novel insights into the interplay of Env, Vpr, Nef, and mannose receptor. The authors make a convincing case that MR affects Env expression in the absence of Vpr and Nef and that MR is responsible for limiting virus spread from MDM to T cells in the absence of Vpr. The manuscript is well written and the experiments are for the most part well-designed and executed. I do have a few issues as detailed below that require the authors attention.

We thank the reviewer for the positive comments. As discussed above, we provided clarification in the revised manuscript that both Nef and Vpr are required but neither are sufficient for maximal MR downregulation.

> 1\) Figure 1: Multiple studies have documented that replication of Vpr-deficient HIV-1 in macrophages is severely restricted when compared to wild type (wt) virus (e.g. Connor et al., 1995). I find it therefore astonishing that in panels C and E of Figure 1, there is only a minor difference in the pr55 levels of cells infected with wt and vpr-null virus. At 10 days post infection I would have expected a much larger difference in the Gag levels. In the figure legend and in the text the authors talk about \"matched infection frequencies\" but they don\'t explain how this was accomplished.

Please see reply to reviewer 1's comment \#5. Briefly, as previously reported (Mashiba et al., 2014), the effect of Vpr on infection frequency is reduced over time as the virus saturates the macrophage culture. Additionally, we have observed that the requirement for Vpr can be minimized by increasing the viral MOI. Thus, by adjusting the inoculum and the duration of the infection, we can often achieve saturating infection of both viruses that allow more direct comparison than if the infection frequencies were very different. For more attenuated viruses, such as those lacking both Vpr and Nef or both Vpr and mutant Env, it was not possible to obtain comparable infection frequencies. These experiments required more adjustments to account for infection frequency differences. This was clarified in the revised manuscript.

> 2\) Also, I find it interesting that the authors go out of their way to document differences in Env levels by showing not only gp160 (the Env equivalent of pr55) but, in addition gp120 and gp41. Yet, they don\'t show p24 (CA). Showing the entire Gag blots (or at least inclusion of CA) might be informative since p24 antibodies typically have a higher affinity to p24 than to the pr55 precursor.

Blots for Gag p24 were included in the analysis for a previously published paper by (Mashiba et al., 2014). In that study we demonstrated no consistent differences in intracellular p24 mediated by Vpr expression across multiple donors. However, we observed more variability with p24 western blots than pr55 western blots -- perhaps because p24 is in the mature virion and can be variably retained in macrophages. Nevertheless, because of the variability, we utilize unprocessed pr55 to normalize for infection in our western blot analyses.

> 3\) How does the strong reduction of MR in Figure 1C at the protein level by just Vpr fit with the data from Figure 2D where both Nef and Vpr were required for efficient cell-surface down-modulation of MR in a single round infection?

As mentioned above, Vpr and Nef are both required but neither is sufficient for maximal MR downregulation. The wild-type virus used in Figure 1C expresses both Nef and Vpr. The loss of Vpr alone causes a significant increase in MR expression relative to wildtype, which is consistent with our findings in Figure 2 that both Nef and Vpr are required to observe strong downmodulation of MR protein

> 4\) Figure 2D and G: How do the authors explain that only a subset of GFP+ cells downregulate MR? They skirt this issue both in the text and in the Discussion. In their Discussion, the authors make a statement concerning the importance of Env expression for Vpr-sensitive restriction in MDM. Since the construct used here is Env-defective, cells should be stained for intracellular p24 to see whether the Gag expression pattern matches that of GFP or MR (obviously it can\'t be both).

Please see also responses to reviewer 2 question 2:

The assays depicted in Figure 2D and 2E (previously 2G) were performed 5 days post transduction whereas the western blots of whole cell lysates were from ten-day cultures (Figure 1D). These data indicate that more striking effects on MR are observed at later time points post infection and suggest MR downregulation is time-dependent in macrophages, which tolerate HIV infection for weeks. This time dependency is potentially explainable in part by the very long half-life of MR (33 hours) (Lennartz, Cole and Stahl, 1989). Additionally, as we mention in the Discussion, MR is present at very high levels on macrophages (100,000 per cell) and it is likely that Vpr and Nef both must achieve high level expression to achieve maximal effect.

Adding a gag stain to the flow cytometry depicted in Figure 2D and E would not be informative, because, as shown in 2A, this construct lacks Gag. GFP, which is in the env ORF as a fusion with the first few amino acids of Env, should effectively mark all infected cells.

> 5\) Figure 1---figure supplement 1: The authors should include a Q65R mutant of Vpr in the analysis to strengthen the argument that Vpr-mediated downmodulation of MR is DCAF1-independent.

We have completed the experiment with the Q65R mutant as suggested. As shown in Figure 2D and E, the vpr-Q65R mutant has a similar defect to vpr-null, which is consistent with a model in which DCAF1 binding is required to downmodulate MR. This was the expected result given our previous findings that the vpr-Q65R mutation was defective at reversing the macrophage-selective restriction of Env expression (Mashiba et al., 2014).

> 6\) Figure 3C/D: Donor 2: The% Gag-positive cells on day 10 is almost identical for wt and vpr-null samples. In contrast, virus output in panel D on day 10 is significantly lower for the vpr-null virus. Does that mean virus spreads mostly in a cell-to-cell manner in MDM? Does it correlate with low MR levels?

We have clarified this important point in the revised manuscript. At earlier time points, the infection rate in the Vpr mutant is lower, indicating that the lower p24 release correlates with slower spread. As discussed above, by day 10 we often see that Wt and Vpr-null infections approach parity because nearly all the cells in the culture become infected.

> 7\) Nef does a lot of things but I am not aware of any literature reporting an effect of Nef on Env stability. What did I miss?

We agree that our results showing that mutating Nef reduces Env stability in macrophages are novel. A likely related effect of Nef in other cell types was previously reported (Lama, Mangasarian and Trono, 1999). This paper demonstrates that CD4 reduces Env levels in virions. This effect of CD4 is thought to be due to CD4 binding Env within infected cells. It is reversed by Nef and Vpu-mediated CD4 downmodulation. We discuss this and how it parallels our model that Env binding to MR interferes with Env trafficking in the revised manuscript. We previously demonstrated that without Vpr, Env and Env containing virions are trafficked to lysosomes and degraded at an accelerated rate. The Vpr/Nef-mediated downmodulation of MR reverses this effect.

> 8\) Figure 3E: Deletion of Nef alone reduces Env expression almost as much as deleting both Nef and Vpr. How can this be explained? Is it correlated with effect on MR expression? A MR western blot should be included here. But even if the effect of Nef deletion involves MR how can this work if Nef only affects MR surface expression and not total cellular pool of MR?

Our data indicate that both Vpr and Nef are required for maximal MR downmodulation, but neither is sufficient. In the revised version of Figure 4E (previously 3E) we provide additional data from a second donor in which the effects of Nef and Vpr mutation are more equal. Similarly, in the single round experiments depicted in 2E we observe some variation in the relative activity of Nef and Vpr. Overall, the compiled results did not show a significant difference between the Vpr mutant and the Nef mutant.

Because the infection frequencies for the mutant viruses shown in this figure are quite low, adding western blots of MR to Figure 4E would not allow us to properly assess the effect of viral proteins on MR. The Nef-null single mutant is defective at spread due to the multifactorial effects of Nef. In the case of Nef-null only about half of MDMs are infected. In the case of Vpr-Nef-null \<20% are infected. Thus, the whole cell lysates largely reflect MR levels of uninfected cells in those samples.

> 9\) Figure 5I: The authors conclude from this experiment that MR restricts Env expression via direct interaction with high-mannose residues on Env. Where in the cell is this happening? What happens if cells are treated with Brefeldin A, which traps Env and MR in the ER? Will it exacerbate/alleviate the effect of MR on Env?

This is an interesting idea but given the broad effects of brefeldin on trafficking and the potential for complex indirect effects, results will be difficult to interpret. For example, brefeldin treatment of Nef expressing cells leads to non-specific reduction of most proteins found on the cell surface and a modest increase in MHC-I. The experiment does not answer the question as to where in the cell Nef is acting. This question asked by the reviewer is better addressed by considering the forms of Env that are affected as well as effects on Env-containing virions that we previously published. We previously showed that Env-containing virions are retained at the cell surface and targeted to lysosomes in macrophages lacking Vpr (Collins et al., 2015). Our prior studies also provided evidence that unprocessed Env is affected and targeted to lysosomal compartments albeit to a lesser degree (Mashiba et al., 2014). Because Env processing occurs via furin-mediated cleavage in the TGN, the effect on unprocessed Env provides evidence that MR interacts with Env along the secretory pathway prior to its arrival and processing in the TGN. A paragraph discussing this interesting question has been added to the revised manuscript.

> 10\) "MR is the restriction factor" -- I would suggest softening this statement to \"MR is a restriction factor\".

This line was softened as suggested.

> 11\) Discussion: \"In the primary macrophage system, Vpr-sensitive virion restriction depends entirely on an intact env open reading frame (Mashiba et al., 2014)\". What are the implications of this statement for the data shown in Figure 2 where Env was replaced by GFP?

We have clarified in the revised manuscript that Env is required for us to observe effects of Vpr on virion release. We propose that this is because MR requires interactions with Env to retain virions. In our model, Env expression is not required for us to observe effects of Vpr or Nef on MR, as demonstrated in Figure 2E.

> 12\) Discussion:\" The magnitude of the effect and the fraction of cells affected increased when both proteins were expressed\". What does the \"fraction of cells\" statement mean? Are the authors suggesting that this is an \"either-or\" phenomenon where Nef downmodulates MR in one fraction of the cells and Vpr does the same but in another fraction and only together do we see downmodulation in the two fractions combined? That would be fantastic from a mechanistical point of view and would explain the results from but is very unrealistic, I am afraid.

We have clarified our interpretation that Vpr and Nef act synergistically in the same cells. Our evidence suggests Vpr and Nef each has a partial effect on its own that is dramatically enhanced in the presence of the other factor. Regarding the fact that only a subset of GFP+ cells are dramatically affected on day five post-infection, as described above, this is likely related to the time-dependent nature of the process.

> 13\) The fourth paragraph of the Discussion is somewhat trivial and can be deleted without loss to content and clarity of the paper. Instead, the authors should simply include the Q65R control as suggested for Supplementary Figure 1 above. That\'s a quick and easy experiment to do.

In response to the reviewer's concern, we tested the ability of the Q65R mutant to downmodulate MR and determined that it behaves similarly to Vpr-null viruses which is consistent with our model (Figure 2E).
